0001812727 false --12-31 2022 Q3 0001812727 2022-01-01 2022-09-30 0001812727 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001812727 RELI:SeriesWarrantsMember 2022-01-01 2022-09-30 0001812727 2022-11-14 0001812727 2022-09-30 0001812727 2021-12-31 0001812727 2022-07-01 2022-09-30 0001812727 2021-07-01 2021-09-30 0001812727 2021-01-01 2021-09-30 0001812727 us-gaap:PreferredStockMember 2021-12-31 0001812727 us-gaap:CommonStockMember 2021-12-31 0001812727 RELI:CommonStockIssuableMember 2021-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001812727 RELI:SubscriptionReceivableMember 2021-12-31 0001812727 us-gaap:RetainedEarningsMember 2021-12-31 0001812727 us-gaap:PreferredStockMember 2022-03-31 0001812727 us-gaap:CommonStockMember 2022-03-31 0001812727 RELI:CommonStockIssuableMember 2022-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001812727 RELI:SubscriptionReceivableMember 2022-03-31 0001812727 us-gaap:RetainedEarningsMember 2022-03-31 0001812727 2022-03-31 0001812727 us-gaap:PreferredStockMember 2022-06-30 0001812727 us-gaap:CommonStockMember 2022-06-30 0001812727 RELI:CommonStockIssuableMember 2022-06-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001812727 RELI:SubscriptionReceivableMember 2022-06-30 0001812727 us-gaap:RetainedEarningsMember 2022-06-30 0001812727 2022-06-30 0001812727 us-gaap:PreferredStockMember 2020-12-31 0001812727 us-gaap:CommonStockMember 2020-12-31 0001812727 RELI:CommonStockIssuableMember 2020-12-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001812727 RELI:SubscriptionReceivableMember 2020-12-31 0001812727 us-gaap:RetainedEarningsMember 2020-12-31 0001812727 2020-12-31 0001812727 us-gaap:PreferredStockMember 2021-03-31 0001812727 us-gaap:CommonStockMember 2021-03-31 0001812727 RELI:CommonStockIssuableMember 2021-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001812727 RELI:SubscriptionReceivableMember 2021-03-31 0001812727 us-gaap:RetainedEarningsMember 2021-03-31 0001812727 2021-03-31 0001812727 us-gaap:PreferredStockMember 2021-05-31 0001812727 us-gaap:CommonStockMember 2021-05-31 0001812727 RELI:CommonStockIssuableMember 2021-05-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001812727 RELI:SubscriptionReceivableMember 2021-05-31 0001812727 us-gaap:RetainedEarningsMember 2021-05-31 0001812727 2021-05-31 0001812727 us-gaap:PreferredStockMember 2021-06-30 0001812727 us-gaap:CommonStockMember 2021-06-30 0001812727 RELI:CommonStockIssuableMember 2021-06-30 0001812727 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001812727 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001812727 RELI:CommonStockIssuableMember 2022-01-01 2022-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001812727 RELI:SubscriptionReceivableMember 2022-01-01 2022-03-31 0001812727 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001812727 2022-01-01 2022-03-31 0001812727 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001812727 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001812727 RELI:CommonStockIssuableMember 2022-04-01 2022-06-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001812727 RELI:SubscriptionReceivableMember 2022-04-01 2022-06-30 0001812727 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001812727 2022-04-01 2022-06-30 0001812727 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001812727 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001812727 RELI:CommonStockIssuableMember 2022-07-01 2022-09-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001812727 RELI:SubscriptionReceivableMember 2022-07-01 2022-09-30 0001812727 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001812727 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001812727 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001812727 RELI:CommonStockIssuableMember 2021-01-01 2021-03-31 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001812727 RELI:SubscriptionReceivableMember 2021-01-01 2021-03-31 0001812727 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001812727 2021-01-01 2021-03-31 0001812727 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001812727 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001812727 RELI:CommonStockIssuableMember 2021-04-01 2021-06-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001812727 RELI:SubscriptionReceivableMember 2021-04-01 2021-06-30 0001812727 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001812727 2021-04-01 2021-06-30 0001812727 us-gaap:PreferredStockMember 2021-06-01 2021-09-30 0001812727 us-gaap:CommonStockMember 2021-06-01 2021-09-30 0001812727 RELI:CommonStockIssuableMember 2021-06-01 2021-09-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-09-30 0001812727 RELI:SubscriptionReceivableMember 2021-06-01 2021-09-30 0001812727 us-gaap:RetainedEarningsMember 2021-06-01 2021-09-30 0001812727 2021-06-01 2021-09-30 0001812727 us-gaap:PreferredStockMember 2022-09-30 0001812727 us-gaap:CommonStockMember 2022-09-30 0001812727 RELI:CommonStockIssuableMember 2022-09-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001812727 RELI:SubscriptionReceivableMember 2022-09-30 0001812727 us-gaap:RetainedEarningsMember 2022-09-30 0001812727 us-gaap:PreferredStockMember 2021-09-30 0001812727 us-gaap:CommonStockMember 2021-09-30 0001812727 RELI:CommonStockIssuableMember 2021-09-30 0001812727 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001812727 RELI:SubscriptionReceivableMember 2021-09-30 0001812727 us-gaap:RetainedEarningsMember 2021-09-30 0001812727 2021-09-30 0001812727 us-gaap:OverAllotmentOptionMember 2021-01-01 2021-03-31 0001812727 2022-01-01 2022-01-31 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember srt:MaximumMember 2020-02-19 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:CommonClassAMember 2020-02-18 2020-02-19 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-10-07 2020-10-08 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-12-01 2020-12-30 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-12-30 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-03-01 2021-03-31 0001812727 RELI:SecuritiesPurchaseAgreementMember RELI:NSUREIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-03-31 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:CustomerMember 2022-01-01 2022-09-30 0001812727 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001812727 us-gaap:MeasurementInputSharePriceMember 2022-09-30 0001812727 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001812727 us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001812727 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001812727 us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001812727 us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001812727 us-gaap:MeasurementInputExpectedDividendRateMember 2022-09-30 0001812727 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001812727 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001812727 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001812727 us-gaap:FairValueInputsLevel3Member RELI:WACCRiskPremiumMember 2022-09-30 0001812727 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001812727 us-gaap:FairValueInputsLevel3Member RELI:CreditSpreadMember 2022-09-30 0001812727 us-gaap:FairValueInputsLevel3Member RELI:PaymentDelayMember 2022-09-30 0001812727 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001812727 RELI:SeriesBWarrantCommitmentMember 2021-12-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2021-12-31 0001812727 RELI:PlacementAgentWarrantsMember 2021-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-01-01 2022-03-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-01-01 2022-03-31 0001812727 RELI:PlacementAgentWarrantsMember 2022-01-01 2022-03-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-03-31 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-03-31 0001812727 RELI:PlacementAgentWarrantsMember 2022-03-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-04-01 2022-06-30 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-04-01 2022-06-30 0001812727 RELI:PlacementAgentWarrantsMember 2022-04-01 2022-06-30 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-06-30 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-06-30 0001812727 RELI:PlacementAgentWarrantsMember 2022-06-30 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-07-01 2022-09-30 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-07-01 2022-09-30 0001812727 RELI:PlacementAgentWarrantsMember 2022-07-01 2022-09-30 0001812727 RELI:SeriesBWarrantCommitmentMember 2022-09-30 0001812727 RELI:SeriesBWarrantLiabilityMember 2022-09-30 0001812727 RELI:PlacementAgentWarrantsMember 2022-09-30 0001812727 RELI:SeriesBWarrantCommitmentMember 2020-12-31 0001812727 RELI:SeriesBWarrantCommitmentMember 2021-01-01 2021-12-31 0001812727 2021-01-01 2021-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001812727 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2022-07-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2022-07-01 2022-09-30 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2022-07-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2022-07-01 2022-09-30 0001812727 RELI:USBenefitsAllianceLLCMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2022-07-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2022-07-01 2022-09-30 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2022-07-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2022-07-01 2022-09-30 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2022-07-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2022-07-01 2022-09-30 0001812727 RELI:FortmanInsuranceServicesLLCMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2022-07-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2022-07-01 2022-09-30 0001812727 RELI:AltruisBenefitsConsultingIncMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:KushMember 2022-07-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:KushMember 2022-07-01 2022-09-30 0001812727 RELI:KushMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:MedigapMember 2022-07-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:MedigapMember 2022-07-01 2022-09-30 0001812727 RELI:MedigapMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:BarraMember 2022-07-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:BarraMember 2022-07-01 2022-09-30 0001812727 RELI:BarraMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:PropertyAndCasualtyMember 2022-07-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-09-30 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-09-30 0001812727 RELI:USBenefitsAllianceLLCMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-09-30 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-09-30 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-09-30 0001812727 RELI:FortmanInsuranceServicesLLCMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-09-30 0001812727 RELI:AltruisBenefitsConsultingIncMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:KushMember 2022-01-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:KushMember 2022-01-01 2022-09-30 0001812727 RELI:KushMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:MedigapMember 2022-01-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:MedigapMember 2022-01-01 2022-09-30 0001812727 RELI:MedigapMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:BarraMember 2022-01-01 2022-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:BarraMember 2022-01-01 2022-09-30 0001812727 RELI:BarraMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:PropertyAndCasualtyMember 2022-01-01 2022-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2021-07-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2021-07-01 2021-09-30 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2021-07-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2021-07-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2021-07-01 2021-09-30 0001812727 RELI:USBenefitsAllianceLLCMember 2021-07-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2021-07-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2021-07-01 2021-09-30 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2021-07-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2021-07-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2021-07-01 2021-09-30 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2021-07-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2021-07-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2021-07-01 2021-09-30 0001812727 RELI:FortmanInsuranceServicesLLCMember 2021-07-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2021-07-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2021-07-01 2021-09-30 0001812727 RELI:AltruisBenefitsConsultingIncMember 2021-07-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:KushMember 2021-07-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:KushMember 2021-07-01 2021-09-30 0001812727 RELI:KushMember 2021-07-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember 2021-07-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:PropertyAndCasualtyMember 2021-07-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2021-01-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:EmployeeBenefitsSolutionsLLCMember 2021-01-01 2021-09-30 0001812727 RELI:EmployeeBenefitsSolutionsLLCMember 2021-01-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2021-01-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:USBenefitsAllianceLLCMember 2021-01-01 2021-09-30 0001812727 RELI:USBenefitsAllianceLLCMember 2021-01-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2021-01-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:CommercialCoverageSolutionsLLCMember 2021-01-01 2021-09-30 0001812727 RELI:CommercialCoverageSolutionsLLCMember 2021-01-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2021-01-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:SouthwesternMontanaFinancialCenterIncMember 2021-01-01 2021-09-30 0001812727 RELI:SouthwesternMontanaFinancialCenterIncMember 2021-01-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2021-01-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:FortmanInsuranceServicesLLCMember 2021-01-01 2021-09-30 0001812727 RELI:FortmanInsuranceServicesLLCMember 2021-01-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2021-01-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:AltruisBenefitsConsultingIncMember 2021-01-01 2021-09-30 0001812727 RELI:AltruisBenefitsConsultingIncMember 2021-01-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember RELI:KushMember 2021-01-01 2021-09-30 0001812727 RELI:PropertyAndCasualtyMember RELI:RegularMember RELI:KushMember 2021-01-01 2021-09-30 0001812727 RELI:KushMember 2021-01-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:RegularMember 2021-01-01 2021-09-30 0001812727 RELI:MedicalLifeMember RELI:PropertyAndCasualtyMember 2021-01-01 2021-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:LTCGlobalMember 2022-01-01 2022-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:PriorityHealthMember 2022-01-01 2022-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:PriorityHealthMember 2021-01-01 2021-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:BlueCrossBlueShieldMember 2022-01-01 2022-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:BlueCrossBlueShieldMember 2021-01-01 2021-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:LTCGlobalMember 2022-07-01 2022-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:LTCGlobalMember 2021-07-01 2021-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:PriorityHealthMember 2022-07-01 2022-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:PriorityHealthMember 2021-07-01 2021-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:BlueCrossBlueShieldMember 2022-07-01 2022-09-30 0001812727 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember RELI:BlueCrossBlueShieldMember 2021-07-01 2021-09-30 0001812727 srt:ScenarioPreviouslyReportedMember 2020-12-31 0001812727 srt:RestatementAdjustmentMember 2020-12-31 0001812727 srt:ScenarioPreviouslyReportedMember 2021-03-31 0001812727 srt:RestatementAdjustmentMember 2021-03-31 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-01-08 2022-01-10 0001812727 RELI:MeasurementInputRoyaltyRateMember us-gaap:TradeNamesMember 2022-09-30 0001812727 us-gaap:MeasurementInputDiscountRateMember us-gaap:TradeNamesMember 2022-09-30 0001812727 us-gaap:MeasurementInputDiscountRateMember us-gaap:CustomerRelationshipsMember 2022-09-30 0001812727 RELI:MeasurementInputObsolescenceRateMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-09-30 0001812727 us-gaap:MeasurementInputDiscountRateMember RELI:BackLogMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-01-01 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2022-01-11 2022-09-30 0001812727 RELI:APAMember RELI:BarraAndAssociatesLLCMember 2022-04-25 2022-04-26 0001812727 RELI:APAMember RELI:BarraAndAssociatesLLCMember RELI:PaidAtClosingMember 2022-04-25 2022-04-26 0001812727 RELI:APAMember RELI:BarraAndAssociatesLLCMember RELI:PayableInSixMonthsMember 2022-04-25 2022-04-26 0001812727 RELI:APAMember RELI:BarraAndAssociatesLLCMember RELI:PayableOverTwoYearsMember 2022-04-25 2022-04-26 0001812727 RELI:APAMember RELI:BarraAndAssociatesLLCMember 2022-04-26 0001812727 RELI:MeasurementInputRoyaltyRateMember us-gaap:TradeNamesMember RELI:BarraMember 2022-09-30 0001812727 us-gaap:MeasurementInputDiscountRateMember us-gaap:TradeNamesMember RELI:BarraMember 2022-09-30 0001812727 us-gaap:MeasurementInputDiscountRateMember us-gaap:CustomerRelationshipsMember RELI:BarraMember 2022-09-30 0001812727 us-gaap:MeasurementInputDiscountRateMember RELI:DevelopedTechnologyMember 2022-09-30 0001812727 RELI:BarraMember 2022-09-30 0001812727 RELI:BarraMember 2022-01-01 2022-09-30 0001812727 RELI:BarraMember 2022-04-27 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:PropertyPlantAndEquipmentMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:PropertyPlantAndEquipmentMember 2022-01-01 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:RightOfUseAssetMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:TradeNamesMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:TradeNamesMember 2022-01-01 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:CustomerRelationshipsMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:BackLogMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:BackLogMember 2022-01-01 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:ChargebackReserveMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember RELI:LeaseLiabilityMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:GoodwillMember 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember us-gaap:GoodwillMember 2022-01-01 2022-09-30 0001812727 RELI:BarraMember RELI:AcquiredAccountsReceivableMember 2022-09-30 0001812727 RELI:BarraMember us-gaap:PropertyPlantAndEquipmentMember 2022-09-30 0001812727 RELI:BarraMember us-gaap:PropertyPlantAndEquipmentMember 2022-01-01 2022-09-30 0001812727 RELI:BarraMember RELI:RightOfUseAssetMember 2022-09-30 0001812727 RELI:BarraMember us-gaap:TradeNamesMember 2022-09-30 0001812727 RELI:BarraMember us-gaap:TradeNamesMember 2022-01-01 2022-09-30 0001812727 RELI:BarraMember us-gaap:CustomerRelationshipsMember 2022-09-30 0001812727 RELI:BarraMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001812727 RELI:BarraMember RELI:AgencyRelationshipsMember 2022-09-30 0001812727 RELI:BarraMember RELI:AgencyRelationshipsMember 2022-01-01 2022-09-30 0001812727 RELI:BarraMember RELI:DevelopedTechnologyMember 2022-09-30 0001812727 RELI:BarraMember RELI:DevelopedTechnologyMember 2022-01-01 2022-09-30 0001812727 RELI:BarraMember RELI:LeaseLiabilityMember 2022-09-30 0001812727 RELI:BarraMember us-gaap:GoodwillMember 2022-09-30 0001812727 RELI:BarraMember us-gaap:GoodwillMember 2022-01-01 2022-09-30 0001812727 RELI:MedigapHealthcareInsuranceCompanyMember 2021-01-01 2021-09-30 0001812727 RELI:BarraMember 2021-01-01 2021-09-30 0001812727 us-gaap:TrademarksAndTradeNamesMember 2022-01-01 2022-09-30 0001812727 us-gaap:TrademarksAndTradeNamesMember 2022-09-30 0001812727 RELI:InternallyDevelopedSoftwareMember 2022-01-01 2022-09-30 0001812727 RELI:InternallyDevelopedSoftwareMember 2022-09-30 0001812727 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001812727 us-gaap:CustomerRelationshipsMember 2022-09-30 0001812727 RELI:PurchasedSoftwareMember 2022-01-01 2022-09-30 0001812727 RELI:PurchasedSoftwareMember 2022-09-30 0001812727 RELI:VideoProductionAssetsMember 2022-01-01 2022-09-30 0001812727 RELI:VideoProductionAssetsMember 2022-09-30 0001812727 RELI:NoncompetitionAgreementsMember 2022-01-01 2022-09-30 0001812727 RELI:NoncompetitionAgreementsMember 2022-09-30 0001812727 RELI:ContractsBacklogMember 2022-01-01 2022-09-30 0001812727 RELI:ContractsBacklogMember 2022-09-30 0001812727 us-gaap:TrademarksAndTradeNamesMember 2021-01-01 2021-12-31 0001812727 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2021-01-01 2021-12-31 0001812727 RELI:InternallyDevelopedSoftwareMember 2021-12-31 0001812727 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0001812727 us-gaap:CustomerRelationshipsMember 2021-12-31 0001812727 RELI:PurchasedSoftwareMember 2021-01-01 2021-12-31 0001812727 RELI:PurchasedSoftwareMember 2021-12-31 0001812727 RELI:VideoProductionAssetsMember 2021-01-01 2021-12-31 0001812727 RELI:VideoProductionAssetsMember 2021-12-31 0001812727 RELI:NoncompetitionAgreementsMember 2021-01-01 2021-12-31 0001812727 RELI:NoncompetitionAgreementsMember 2021-12-31 0001812727 RELI:EBSandUSBAMember 2022-09-30 0001812727 RELI:EBSandUSBAMember 2021-12-31 0001812727 RELI:CCSMember 2022-09-30 0001812727 RELI:CCSMember 2021-12-31 0001812727 RELI:SWMTMember 2022-09-30 0001812727 RELI:SWMTMember 2021-12-31 0001812727 RELI:FISMember 2022-09-30 0001812727 RELI:FISMember 2021-12-31 0001812727 RELI:ABCMember 2022-09-30 0001812727 RELI:ABCMember 2021-12-31 0001812727 RELI:BarraMember 2021-12-31 0001812727 RELI:DirectorsAndOfficerMember 2022-09-30 0001812727 RELI:DirectorsAndOfficerMember 2021-12-31 0001812727 RELI:DirectorsAndOfficerMember 2022-01-01 2022-09-30 0001812727 RELI:DirectorsAndOfficerMember 2021-01-01 2021-12-31 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember srt:MaximumMember 2021-12-22 0001812727 RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 us-gaap:CommonStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-21 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-21 2021-12-22 0001812727 RELI:SeriesBConvertiblePreferredStockMember RELI:SecuritiesPurchaseAgreementMember 2021-12-22 0001812727 RELI:SecuritiesPurchaseAgreementMember 2021-01-01 2021-12-31 0001812727 RELI:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember 2022-01-05 0001812727 us-gaap:PrivatePlacementMember RELI:SecuritiesPurchaseAgreementMember 2022-01-04 2022-01-05 0001812727 us-gaap:PrivatePlacementMember RELI:SecuritiesPurchaseAgreementMember 2022-07-01 2022-09-30 0001812727 us-gaap:PrivatePlacementMember RELI:SecuritiesPurchaseAgreementMember 2022-01-01 2022-09-30 0001812727 us-gaap:PrivatePlacementMember RELI:SecuritiesPurchaseAgreementMember 2022-09-30 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-01-31 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-09-30 0001812727 RELI:SeriesBConvertiblePreferredStockMember 2022-08-08 2022-08-09 0001812727 us-gaap:CommonStockMember 2022-08-08 2022-08-09 0001812727 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-01-01 2022-01-31 0001812727 RELI:MedigapAcquisitionMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantMember 2022-01-31 0001812727 us-gaap:CommonStockMember 2022-01-01 2022-01-31 0001812727 us-gaap:CommonStockMember 2022-03-01 2022-03-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-06-30 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-06-30 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-07-31 0001812727 us-gaap:CommonStockMember 2022-07-31 0001812727 RELI:SeriesAWarrantsMember 2022-09-30 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-01-31 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-09-30 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-01-31 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-01-31 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-01-31 0001812727 RELI:SeriesCandDWarrantsMember 2022-09-30 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-05-01 2022-05-31 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-06-01 2022-06-30 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-05-01 2022-05-31 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-06-01 2022-06-30 0001812727 RELI:SeriesCPrepaidWarrantsMember 2022-05-31 0001812727 RELI:SeriesCPrepaidWarrantsMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-07-01 2022-07-31 0001812727 RELI:SeriesDPrepaidWarrantsMember us-gaap:CommonStockMember 2022-07-01 2022-07-31 0001812727 RELI:SeriesDPrepaidWarrantsMember 2022-07-31 0001812727 us-gaap:CommonStockMember 2022-04-30 0001812727 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001812727 RELI:SeriesBAndPlacementAgentWarrantsMember 2022-07-01 2022-09-30 0001812727 RELI:SeriesBAndPlacementAgentWarrantsMember 2022-01-01 2022-09-30 0001812727 RELI:StockOptionsMember 2022-07-01 2022-09-30 0001812727 RELI:StockOptionsMember 2021-07-01 2021-09-30 0001812727 RELI:SeriesAWarrantsMember 2022-07-01 2022-09-30 0001812727 RELI:SeriesAWarrantsMember 2021-07-01 2021-09-30 0001812727 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001812727 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001812727 RELI:UnvestedStockAwardsMember 2022-07-01 2022-09-30 0001812727 RELI:UnvestedStockAwardsMember 2021-07-01 2021-09-30 0001812727 RELI:StockOptionsMember 2022-01-01 2022-09-30 0001812727 RELI:StockOptionsMember 2021-01-01 2021-09-30 0001812727 RELI:SeriesAWarrantsMember 2022-01-01 2022-09-30 0001812727 RELI:SeriesAWarrantsMember 2021-01-01 2021-09-30 0001812727 RELI:PlacementAgentWarrantsMember 2022-01-01 2022-09-30 0001812727 RELI:PlacementAgentWarrantsMember 2021-01-01 2021-09-30 0001812727 us-gaap:PreferredStockMember 2022-01-01 2022-09-30 0001812727 us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001812727 RELI:UnvestedStockAwardsMember 2022-01-01 2022-09-30 0001812727 RELI:UnvestedStockAwardsMember 2021-01-01 2021-09-30 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2021-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2021-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2021-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2021-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2022-01-01 2022-09-30 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2022-01-01 2022-09-30 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2022-01-01 2022-09-30 0001812727 RELI:JPKushAndAssociatesIncMember 2022-01-01 2022-09-30 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2022-09-30 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2022-09-30 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2022-09-30 0001812727 RELI:JPKushAndAssociatesIncMember 2022-09-30 0001812727 RELI:CommercialSolutionsOfInsuranceAgencyLLCMember 2020-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2020-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2020-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2020-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2020-12-31 0001812727 RELI:CommercialSolutionsOfInsuranceAgencyLLCMember 2021-01-01 2021-12-31 0001812727 RELI:FortmanInsuranceAgencyLLCMember 2021-01-01 2021-12-31 0001812727 RELI:SouthwesternMontanaInsuranceCenterIncMember 2021-01-01 2021-12-31 0001812727 RELI:AltruisBenefitsConsultantsIncMember 2021-01-01 2021-12-31 0001812727 RELI:JPKushAndAssociatesIncMember 2021-01-01 2021-12-31 0001812727 RELI:CommercialSolutionsOfInsuranceAgencyLLCMember 2021-12-31 0001812727 RELI:YESAmericanaGroupLLCMember 2022-09-13 0001812727 RELI:YESAmericanaGroupLLCMember 2022-09-12 2022-09-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission file number of the issuing entity: 001-40020

 

RELIANCE GLOBAL GROUP, INC.

(Exact name of registrant as specified in its charter)

 

Florida   46-3390293

(State or other jurisdiction

of incorporation or organization)

  

(I.R.S. Employer

Identification Number)

 

524210

(Primary Standard Industrial Code Classification Number)

 

300 Blvd. of the Americas, Suite 105 Lakewood, NJ 08701

732-380-4600

(Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   RELI   The Nasdaq Capital Market
Series A Warrants   RELIW   Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes: ☒ No: ☐

 

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes: ☒ No: ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company, in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer ☒   Smaller reporting company ☒
Emerging Growth Company ☐    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act).

 

Yes: ☐ No: ☒

 

At November 14, 2022 the registrant had 18,054,469 shares of common stock, par value $0.086 per share, outstanding.

 

 

 

 
 

 

TABLE OF CONTENTS

 

PART I  
Item 1. Financial Statements 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 24
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 33
Item 4. Controls and Procedures. 33
PART II  
Item 1. Legal Proceedings. 33
Item 1A. Risk Factors. 34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 34
Item 3. Defaults Upon Senior Securities. 34
Item 4. Mine Safety Disclosures. 34
Item 5. Other Information. 34
Item 6. Exhibits 34

 

2
 

 

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

 

  

September 30,

2022

  

December 31,

2021

 
Assets          
Current assets:          
Cash  $1,615,054   $4,136,180 
Restricted cash   1,409,562    484,542 
Accounts receivable   1,025,120    1,024,831 
Accounts receivable, related parties   1,159    7,131 
Note receivables   -    - 
Other receivables   37,674    - 
Prepaid expense and other current assets   399,506    2,328,817 
Total current assets   4,488,075    7,981,501 
           
Property and equipment, net   199,030    130,359 
Right-of-use assets   1,327,361    1,067,734 
Investment in NSURE, Inc.   1,350,000    1,350,000 
Intangibles, net   14,359,973    7,078,900 
Goodwill   33,486,107    10,050,277 
Other non-current assets   23,284    16,792 
Total assets  $55,233,830   $27,675,563 
           
Liabilities and stockholders’ equity (deficit)          
Current liabilities:          
Accounts payable and other accrued liabilities  $1,221,583   $2,759,160 
Other payables   1,241,341    81,500 
Chargeback reserve   1,350,533    - 
Short term Financing Agreements   309,993    - 
Current portion of long-term debt   1,026,541    913,920 
Current portion of leases payable   538,018    276,009 
Earn-out liability, current portion   2,283,380    3,297,855 
Warrant commitment   -    37,652,808 
Total current liabilities   7,971,389    44,981,252 
           
Loans payable, related parties, less current portion   1,679,560    353,766 
Long term debt, less current portion   12,640,673    7,085,325 
Leases payable, less current portion   833,395    805,326 
Earn-out liability, less current portion   635,647    516,023 
Warrant liabilities   3,107,578    - 
Total liabilities   26,868,242    53,741,692 
Stockholders’ equity (deficit):          
Preferred stock, $0.086 par value; 750,000,000 shares authorized and 0 issued and outstanding as of September 30, 2022 and December 31, 2021   -    - 
Common stock, $0.086 par value; 2,000,000,000 shares authorized and 18,054,469 and 10,956,109 issued and outstanding as of September 30, 2022 and December 31, 2021, respectively   1,551,358    940,829 
Additional paid-in capital   34,314,591    26,451,187 
Stock subscription receivable   -    (20,000,000)
Accumulated deficit   (7,500,361)   (33,458,145)
Total stockholders’ equity (deficit)   28,365,588    (26,066,129)
Total liabilities and stockholders’ equity (deficit)  $55,233,830   $27,675,563 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

3
 

 

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

 

   2022   2021   2022   2021 
  

Three months ended

September 30,

  

Nine months ended

September 30,

 
   2022   2021   2022   2021 
Revenue                    
Commission income  $4,153,361   $2,581,636   $12,596,268   $7,096,213 
Total revenue   4,153,361    2,581,636    12,596,268    7,096,213 
                     
Operating expenses                    
Commission expense   862,857    660,708    2,617,140    1,748,451 
Salaries and wages   2,114,730    1,188,267    6,373,697    3,217,441 
General and administrative expenses   1,253,097    755,130    5,465,384    2,961,881 
Marketing and advertising   726,115    65,010    1,922,520    143,110 
Depreciation and amortization   713,444    387,729    2,077,372    1,090,183 
Total operating expenses   5,670,243    3,056,844    18,456,113    9,161,066 
                     
Loss from operations   (1,516,882)   (475,208)   (5,859,845)   (2,064,853)
                     
Other income (expense)                    
Other expense, net   (280,340)   (120,025)   (580,900)   (421,192)
Recognition and change in fair value of warrant liabilities   7,919,315    -    32,398,530    - 
Total other income (expense)   7,638,975    (120,025)   31,817,630    (421,192)
                     
Net income (loss)  $6,122,093   $(595,233)  $25,957,785   $(2,486,045)
                     
Basic earnings (loss) per share  $ 0.35   $(0.05)  $ 1.10   $(0.25)
Diluted earnings (loss) per share  $ (0.10)  $(0.05)  $ (0.78)  $(0.25)
Weighted average number of shares outstanding - Basic   17,424,267    10,944,439    17,320,146    9,809,092 
Weighted average number of shares outstanding - Diluted   17,424,267    10,944,439    17,320,146    9,809,092 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

4
 

 

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   capital   Receivable   Deficit   Total 
   Reliance Global Group, Inc. 
   Preferred stock   Common stock   Common stock issuable   Additional paid-in   Subscription   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   capital   Receivable   Deficit   Total 
                                         
Balance, December 31, 2021   -   $-    10,956,109   $940,829    -   $-   $26,451,187   $(20,000,000)  $(33,458,145)  $(26,066,129)
                                                   
Share based compensation   -    -    -    -    -    -    739,960    -    -    739,960 
                                                   
Shares issued due to private placement   9,076    781    2,670,892    229,694    -    -    (230,424)   20,000,000    -    20,000,051 
                                                   
Shares issued pursuant to acquisition of Medigap   -    -    606,037    52,119    -    -    4,711,332    -    -    4,763,451 
                                                   
Exercise of Series A warrants   -    -    375,000    32,250    -    -    2,442,750    -    -    2,475,000 
                                                   
Issuance of prefunded Series C Warrants in exchange for common shares   -    -    (3,276,929)   (281,815)   -    -    281,815    -    -    - 
                                                   
Shares issued for vested stock awards   -    -    6,000    516    -    -    (516)   -    -    - 
                                                   
Net Income   -    -    -    -    -    -    -    -    9,340,000    9,340,000 
                                                   
Balance, March 31, 2022   9,076   $781    11,337,109   $973,593    -   $-   $34,396,104   $-   $(24,118,145)  $11,252,333 
                                                   
Share based compensation   -    -    -    -    -    -    179,083    -    -    179,083 
                                                   
Issuance of common stock for conversion of Series C warrants    -    -    3,276,929    281,815    -    -    (280,479)   -    -    1,336 
                                                   
Net Income   -    -    -    -    -    -    -    -    10,495,691    10,495,691 
                                                   
Balance, June 30, 2022   9,076   $781    14,614,038   $1,255,408    -   $-   $34,294,708   $-   $(13,622,454)  $21,928,443 
                                                   
Share based compensation   -    -    -    -    -    -    314,257    -    -    314,257 
                                                   
Issuance of common stock for conversion of Series D warrants   -    -    1,221,347    105,100    -    -    (104,305)   -    -    795 
                                                   
Shares issued due to conversion of preferred stock   (9,076)   (781)   2,219,084    190,850    -    -    (190,069)   -    -    - 
                                                   
Net Income   -    -    -    -    -    -    -    -    6,122,093    6,122,093 
                                                   
Balance, September 30, 2022   -   $-   18,054,469   $1,551,358       -   $     -   $34,314,591   $-   $(7,500,361)  $28,365,588

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

5
 

 

Reliance Global Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   capital   Deficit   Total 
   Reliance Global Group, Inc. 
   Preferred stock   Common stock   Common stock issuable   Additional paid-in   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   capital   Deficit   Total 
Balance, December 31, 2020   395,640   $33,912    4,241,028   $363,517    23,341   $340,000   $11,559,239 - $(12,359,680)  $(63,012

)

                                              
Share based compensation   -    -    -    -    -    -    246,966    -    246,966 
                                              
Shares issued for services   -    -    15,000    1,290    -    -    89,760    -    91,050 
                                              
Shares issued due to public offering, net of offering costs of $1,672,852   -    -    1,800,000    154,800    -    -    8,954,348    -    9,109,148 
                                              
Over-allotment shares from offering, net of offering costs of $250,928   -    -    270,000    23,220    -    -    1,343,153    -    1,366,373 
                                              
Warrants sold during public offering at quoted price   -    -    -         -    -    20,700    -    20,700 
                                              
Shares issued due to conversion of preferred stock   (394,493)   (33,812)   3,944,930    339,264    -    -    (305,452)   -    - 
                                              
Shares issued due to conversion of debt   -    -    633,333    54,467    -    -    3,745,533    -    3,800,000 
                                              
Rounding shares related to initial public offering   -    -    1,885    -    (3)   -    -    -    - 
                                              
Shares issued pursuant to software purchase   -    -    23,338    1,984    (23,338)   (340,000)   338,016    -    - 
                                              
Net loss   -    -    -    -    -    -    - -  (613,926)   (613,926)
                                              
Balance, March 31, 2021   1,147   $100    10,929,514   $938,542    -   $-   $25,992,263 - $(12,973,606)  $13,957,299 
                                              
Share based compensation   -    -    -    -    -    -    183,132    -    183,132 
                                              
Rounding shares related to initial public offering   20    -    -    -    -    -    -    -    - 
                                              
Shares issued pursuant to acquisition of Kush   -    -    14,925    1,284    -    -    48,716    -    50,000 
                                              
Net loss   -    -    -    -    -    -    - -  (1,276,886)   (1,276,886)
                                              
Balance, June 30, 2021   1,167   $100    10,944,439   $939,826    -   $-   $

26,224,111

 - $(14,250,492)  $

12,913,545

 
                                              
Share based compensation   -    -    -    -    -    -    146,225    -    146,225 
                                              
Rounding shares related to initial public offering   -    -    -    -    -    -    -    -    - 
                                              
Shares issued pursuant to acquisition of Kush   -    -    -    -    -    -    -    -    - 
                                              
Net loss   -    -    -    -    -    -    - -  (595,233)   (595,233)
                                              
Balance, September 30, 2021   1,167   $100    10,944,439   $939,826    -   $-   $26,370,336 - $(14,845,725)  $12,464,537 

 

The accompanying notes are an integral p9rt of these condensed consolidated financial statements

 

6
 

 

Reliance Global Group, Inc. and Subsidiaries and Predecessor

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   2022   2021 
  

Nine months ended

September 30,

 
   2022   2021 
Cash flows from operating activities:          
Net income (loss)  $25,957,785   $(2,486,045)
Adjustment to reconcile net income (loss) to net cash used in operating activities:          
Depreciation and amortization   2,077,372    1,090,183 
Amortization of debt issuance costs and accretion of debt discount   28,702    37,822 
Non-cash lease expense   30,451    2,331 
Stock compensation expense   1,233,300    667,373 
Earn-out fair value and write-off adjustments   132,445   - 
Recognition and change in fair value of warrant liabilities   (32,398,530)   - 
Change in operating assets and liabilities:          
Accounts payables and other accrued liabilities   (1,541,037)   (314,045)
Accounts receivable   92,297    (87,058)
Accounts receivable, related parties   5,972    (7,131)
Other receivables   (37,674)   3,825 
Other payables   34,841    (112) 
Charge back reserve   (133,940)   - 
Other non-current assets   (6,492)   (14,992)
Prepaid expense and other current assets   2,346,510    (196,471)
Net cash used in operating activities   (2,177,998)   (1,304,320)
           
Cash flows from investing activities:          
Purchase of property and equipment   (67,906)   (24,257)
Business acquisitions, net of cash acquired   (24,138,750)   (1,608,586)
Purchase of intangibles   (775,953)   (331,054)
Net cash used in investing activities   (24,982,609)   (1,963,897)
           
Cash flows from financing activities:          
Principal repayments of debt   (663,016)   (663,907)
Proceeds from loan for business acquisition   6,520,000    - 
Payment of debt issuance costs   (214,257)   - 
Payments on earn-out liabilities   (1,627,296)   (452,236)
Proceeds from loans payable, related parties   1,500,000    2,931 
Payments of loans payable, related parties   (174,206)   (504,899)
Proceeds from exercise of warrants into common stock   2,477,131    - 
Repayments on short-term financing   (107,206)     
Net proceeds from private placement issuance of shares and warrants   17,853,351    - 
Issuance of common stock   -    10,496,221 
Net cash provided by financing activities   25,564,501    8,878,110 
           
Net (decrease) increase in cash and restricted cash   (1,596,106)   5,609,893 
Cash and restricted cash at beginning of period   4,620,722    529,581 
Cash and restricted cash at end of period  $3,024,616   $6,139,474 
           
Supplemental disclosure of cash and non-cash investing and financing transactions:          
Cash paid for interest  $562,800   $350,175 
Issuance of series D warrants  $6,930,335   $- 
Issuance of placement agent warrants  $1,525,923   $- 
Prepaid insurance acquired through short-term financing  $417,199   $- 
Conversion of preferred stock into common stock  $190,069   $339,264 
Conversion of debt into equity  $-   $3,800,000 
Cashless conversion of series D warrants into common stock  $

36,761

   $- 
Common stock issued pursuant to acquisition  $4,763,451   $50,000 
Common stock issued in lieu of services  $-   $91,050 
Issuance of common stock pursuant to the purchase of software  $-   $340,000 
Acquisition of business deferred purchase price  $1,125,000   $- 
Lease assets acquired in exchange for lease liabilities  $628,004   $

861,443

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

7
 

 

Reliance Global Group, Inc. and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

 

NOTE 1. SUMMARY OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

 

Reliance Global Group, Inc., formerly known as Ethos Media Network, Inc. (“RELI”, “Reliance”, or the “Company”) incorporated in Florida on August 2, 2013.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of recurring accruals) necessary for a fair presentation have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto, set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Reliance Global Group, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

 

Liquidity

 

As of September 30, 2022, the Company’s reported cash and restricted cash aggregated balance was approximately $3,024,000, current assets were approximately $4,488,000, while current liabilities were approximately $7,971,000. As of September 30, 2022, the Company had a working capital deficit of approximately $3,483,000 and stockholders’ equity of approximately $28,366,000. For the nine months ended September 30, 2022, the Company reported loss from operations of approximately $5,860,000, a non-cash, non-operating gain on the recognition and change in fair value of warrant liabilities of approximately $32,399,000, resulting in an overall net income of approximately $25,958,000. For the nine months ended September 30, 2022, the Company reported negative cash flows from operations of approximately $2,178,000. The Company completed a capital offering in January 2022 that raised net proceeds of approximately $17,853,000. Management believes the Company’s financial position and its ability to raise capital to be reasonable and sufficient.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

 

Cash and Restricted Cash

 

Cash and restricted cash reported on our Condensed Consolidated Balance Sheets are reconciled to the total shown on our Condensed Consolidated Statements of Cash Flows as follows:

 

   September 30, 2022   September 30, 2021 
Cash  $1,615,054   $5,655,103 
Restricted cash   1,409,562    484,371 
Total cash and restricted cash  $3,024,616   $6,139,474 

 

8
 

 

Fair Value of Financial Instruments

 

Level 1 — Observable inputs reflecting quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2 — Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and

Level 3 — Unobservable inputs for the asset or liability, which include management’s own assumption about the assumptions market participants would use in pricing the asset or liability, including assumptions about risk.

 

Warrant Liabilities: The Company re-measures fair value of its Level 3 warrant liabilities at the balance sheet date, using a binomial option pricing model. The following summarizes the significant unobservable inputs:

 

   September 30, 2022  

December 31,

2021

 
Stock price  $0.78    $6.44 
Volatility   105 %   90%
Time to expiry   4.26     5 
Dividend yield   0 %   0%
Risk free rate   4.10 %   1.10%

 

The following reconciles fair value of the liability classified warrants:

    1    2    3    4 
   Three and Nine Months ended September 30, 2022 
   Series B Warrant Commitment   Series B warrant liabilities   Placement agent warrants   Total 
Beginning balance  $37,652,808   $-   $-   $37,652,808 
Initial recognition   -    55,061,119    1,525,923    56,587,042 
Unrealized (gain) loss   17,408,311    (31,980,437)   (946,461)   (15,518,587)
Warrants exercised or transferred   (55,061,119)             (55,061,119)
Ending balance, March 31, 2022  $-   $23,080,682   $579,462   $23,660,144 
Unrealized (gain) loss   -    (12,322,737)   (310,514)   (12,633,251)
Ending balance, June 30, 2022  $-   $10,757,945   $268,948   $11,026,893 
Unrealized (gain) loss   -    (7,726,161)   (193,154)   (7,919,315)
Ending balance, September 30, 2022   -    3,031,784    75,794    3,107,578 

 

    1    2 
   December 31, 2021 
   Series B Warrant Commitment   Total 
Beginning balance  $-   $- 
Initial recognition   20,244,497    20,244,497 
Unrealized (gain) loss   17,408,311    17,408,311 
Ending balance  $37,652,808   $37,652,808 

 

Earn-out liabilities: The Company generally values its Level 3 earn-out liabilities using the income valuation approach. Key valuation inputs include contingent payment arrangement terms, projected revenues and cash flows, rate of return, and probability assessments. The following table summarizes the significant unobservable inputs used in the fair value measurements:

 

    September 30, 2022   December 31, 2021
Valuation technique   Discounted cash flow   Discounted cash flow
Significant unobservable input   Projected revenue and probability of achievement   Projected revenue and probability of achievement

 

9
 

 

The Company values its Level 3 earn-out liability related to the Barra Acquisition using a Monte Carlo simulation in a risk-neutral framework (a special case of the Income Approach). The following summarizes the significant unobservable inputs:

 

    

September 30,

2022

 
WACC Risk Premium:   14.5 %
Volatility   50 %
Credit Spread:   15.1 %
Payment Delay (days)   90 %
Risk free rate   USD Yield Curve  
Discounting Convention:   Mid-period  
Number of Iterations   100,000  

 

Undiscounted remaining earn out payments are approximately $3,291,883 as of September 30, 2022. The following table reconciles fair value of earn-out liabilities for the period ending September 30, 2022:

 

   September 30, 2022   December 31, 2021 
Beginning balance – January 1  $3,813,878  $2,931,418 
         
Acquisitions and Settlements   (1,027,296)    1,160,562 
           
Period adjustments:          
Fair value changes included in earnings*   132,445   (278,102)
           
Ending balance  $2,919,027   $3,813,878 
Less: Current portion   (2,283,380)   (3,297,855)
Ending balance, less current portion   635,647    516,023 

 

* Recorded as a reduction to general and administrative expenses

 

Investment in Nsure

 

On February 19, 2020, the Company entered into a securities purchase agreement with NSURE, Inc. (“NSURE”), which was further amended on October 8, 2020, and as amended provides that the Company may invest up to an aggregate of $5,700,000 in NSURE to be funded in three tranches. In exchange, the Company will receive a total of 928,343 shares of NSURE’s Class A Common Stock.

 

During the course of calendar year 2020 and by October 8, 2020, the Company funded the first tranche, $1,350,000 in exchange for 394,029 shares. The second tranche allowed the Company to acquire an additional 209,075 shares at a price of $6.457 per share by no later than December 30, 2020. The third full tranche allowed the Company to purchase an additional 325,239 shares at a purchase price of $9.224 after December 20, 2020, but no later than March 31, 2021.

 

The Company did not fund tranches two and three in the required timeframes, thus, the Company relinquished its rights under the contract to any additional NSURE shares aside for the ones already acquired with tranche one.

 

10
 

 

The Company measures the NSURE shares subsequent to acquisition in accordance with ASC 321-10-35-2, at cost less impairment since no readily determinable fair value is available to the Company. The investment is reviewed for impairment at each reporting period by qualitatively assessing any indicators demonstrating fair value of the investment is less than carrying value. The Company did not observe any price changes resulting from orderly transactions for identical or similar assets for the periods ended September 30, 2022 or September 30, 2021. ASC 321-10-50-4 further requires an entity to disclose unrealized gains and losses for periods that relate to equity securities held at a reporting date. To-date, the Company has not recognized any unrealized gains or losses on the NSURE security.

 

In accordance with ACS 321-10-35-3, the Company performed a qualitative assessment to determine if the investment may be impaired. After considering the indicators contained in ASC 321-10-35-3a –3e, the Company determined that the investment was not impaired.

 

Revenue Recognition

 

The following table disaggregates the Company’s revenue by line of business, showing commissions earned:

 

Three Months ended September 30, 2022  Medical/Life   Property and Casualty   Total 
Regular               
EBS  $212,384   $-   $212,384 
USBA   13,732    -    13,732 
CCS/UIS   -    76,035    76,035 
Montana   426,591    -    426,591 
Fortman   259,255    186,860    446,115 
Altruis   896,012    -    896,012 
Kush   366,219    -    366,219 
Medigap   1,331,593    -    1,331,593 
Barra   83,615    301,065    384,680 
   $3,589,401   $563,960   $4,153,361 

 

11
 

 

Nine Months ended September 30, 2022  Medical/Life   Property and Casualty   Total 
Regular               
EBS  $645,217   $-   $645,217 
USBA   39,638    -    39,638 
CCS/UIS   -    177,111    177,111 
Montana   1,385,017    -    1,385,017 
Fortman   949,189    589,924    1,539,113 
Altruis   3,056,257    -    3,056,257 
Kush   1,230,259    -    1,230,259 
Medigap   3,868,654    -    3,868,654 
Barra   153,539    501,463    655,002 
   $11,327,770   $1,268,498   $12,596,268 

 

Three Months ended September 30, 2021  Medical/Life   Property and Casualty   Total 
Regular               
EBS   226,233    -    226,233 
USBA   18,241    -    18,241 
CCS/UIS   -    120,762    120,762 
Montana   343,546    -    343,546 
Fortman   357,638    194,218    551,856 
Altruis   807,775    -    807,775 
Kush   513,223    -    513,223 
   $2,266,656   $314,980   $2,581,636 

 

Nine Months ended September 30, 2021  Medical/Life   Property and Casualty   Total 
Regular               
EBS  $642,428   $-   $642,428 
USBA   45,861    -    45,861 
CCS/UIS   -    274,928    274,928 
Montana   1,283,402    -    1,283,402 
Fortman   884,073    628,327    1,512,400 
Altruis   2,558,653    -    2,558,653 
Kush   778,541    -    778,541 
                
   $6,192,958   $903,255   $7,096,213 

 

The following, are customers representing 10% or more of total revenue:

 

Insurance Carrier   2022    2021 
    For the three months ended September 30, 
Insurance Carrier   2022    2021 
LTC Global   27 %    -% 
Priority Health   21 %    27% 
BlueCross BlueShield   10 %    24% 

 

12
 

 

Insurance Carrier   2022    2021 
    For the Nine months ended September 30, 
Insurance Carrier   2022    2021 
LTC Global   27 %   -%
Priority Health   24 %   30%
BlueCross BlueShield   10 %   25%

 

No other single Customer accounted for more than 10% of the Company’s commission revenues. The loss of any significant customer, including Priority Health, BlueCross BlueShield and LTC Global could have a material adverse effect on the Company.

 

Income Taxes

 

The Company recorded no income tax expense for the three and nine months ended September 30, 2022 and 2021 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

 

As of September 30, 2022 and December 31, 2021, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

 

Prior Period Adjustments 

 

The Company identified certain immaterial adjustments impacting prior reporting periods. Specifically, the Company identified adjustments to correct certain asset, liability and equity accounts in relation to historical purchase price allocation accounting, historical accrued revenues and true ups of the common stock issuable account.

 

The Company assessed the materiality of the adjustments to prior period financial statements in accordance with Securities and Exchange Commission Staff Accounting Bulletin No. (SAB) 99, Materiality, and SAB 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, and ASC 250, Accounting Changes and Error Corrections.

 

Accordingly, the Company’s comparative condensed consolidated financial statements and impacted notes have been revised from amounts previously reported to reflect these adjustments. The following table illustrates the impact on previously reported amounts and adjusted balances presented in the condensed consolidated financial statements for the period ended September 30, 2022.

 

Account 

12/31/2020

As reported

   Adjustment  

12/31/2020

Adjusted

 
Earn-out liability   2,631,418    300,000    2,931,418 
Goodwill   9,265,070    (503,345)   8,761,725 
Common stock issuable   822,116    (482,116)   340,000 
Additional paid-in-capital   11,377,123    182,116    11,559,239 
Accumulated Deficit   (12,482,281)   122,601    (12,359,680)

 

Account 

3/31/2021

As reported

   Adjustment  

3/31/2021

Adjusted

 
Common stock issuable   482,116    (482,116)   0 
Additional paid-in-capital   25,810,147    182,116    25,992,263 
Accumulated Deficit   (13,123,609)   150,003    (12,973,606)

 

13
 

 

 

Recently Issued Accounting Pronouncements

 

We do not expect any recently issued accounting pronouncements to have a material effect on our financial statements.

 

NOTE 2. STRATEGIC INVESTMENTS AND BUSINESS COMBINATIONS

 

Medigap Healthcare Insurance Company, LLC Transaction

 

On January 10, 2022, pursuant to an asset purchase agreement, dated December 21, 2021, the Company completed the acquisition of all of the assets of Medigap Healthcare Insurance Company, LLC (“Medigap”) for a purchase price of $20,096,250, consisting of: (i) payment to Medigap of $18,138,750 in cash and (ii) the issuance to Medigap of 606,037 shares of the Company’s restricted common stock in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties. The shares issued to Medigap as part of the purchase price are further subject to lock up arrangements pursuant to which 50% of the shares may be sold after the one-year anniversary of the date of closing of the transaction and the balance of the shares may be sold after the second-year anniversary of the date of closing of the transaction.

 

The acquisition of Medigap was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

 

The preliminary allocation of the purchase price in connection with the acquisition of Medigap was calculated as follows:

 

Description  Fair Value   Weighted Average
Useful Life (Years)		 
Property, plant and equipment  $20,666    5 
Right-of-use asset   317,787      
Trade names   340,000    15 
Customer relationships   4,550,000    12 
Technology   67,000    3 
Backlog   210,000    1 
Chargeback reserve   (1,484,473)     
Lease liability   (317,787)     
Goodwill   19,199,008    Indefinite 
   $22,902,201      

 

Trade name was measured at fair value using the relief-from-royalty method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue from the trade name, a pre-tax royalty rate of 0.5% and a discount rate of 11.0%.

 

Customer relationships were measured at fair value using the multiple-period excess earnings method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue and costs associated with existing customers, and a discount rate of 11.0%.

 

Technology was measured at fair value using the cost replacement method of the cost approach. Significant inputs used to measure the fair value include an estimate of cost to replace, an obsolescence rate of 40.3%.

 

14
 

 

The value assigned to backlog acquired was estimated based upon the contractual nature of the backlog as of the acquisition date, using the income approach to discount back to present value the cash flows attributable to the backlog, using a discount rate of 11.0%.

 

Goodwill of $19,199,008 arising from the acquisition of Medigap consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Medigap is currently expected to be deductible for income tax purposes. Total acquisition costs for the acquisition of Medigap incurred were $94,065 recorded as a component of General and administrative expenses.

 

The approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from January 10, 2022 to September 30, 2022 was $3,868,654 and a loss of $693,861, respectively.

 

Pro Forma Information

 

The results of operations of Medigap will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental pro-forma financial information approximate combined financial information assumes that the acquisition had occurred at the beginning of the nine months ended September 30, 2022 and 2021:

 

   September 30,   September 30, 
   2022   2021 
Revenue  $12,962,843   $10,931,340 
Net Income (Loss)  $25,971,268   $(2,344,977)
Earnings (Loss) per common share, basic  $1.10    $(0.24)
Earnings (Loss) per common share, diluted  $(0.78)  $(0.24)

 

Barra & Associates, LLC Transaction

 

On April 26, 2022, the Company entered into an asset purchase agreement (the “APA”) with Barra & Associates, LLC (“Barra”) pursuant to which the Company purchased all of the assets of Barra & Associates, LLC on April 26, 2022 for a purchase price in the amount of $7,725,000 in cash, with $6,000,000 paid to Barra at closing, $1,125,000 payable in six months from closing, and a final estimated earnout of $600,000 payable over two years from closing, based upon meeting stated milestones. The source of the cash payment was $6,520,000 in funds borrowed from Oak Street Lending (“Loan”), the Company’s existing lender pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties.

 

The acquisition of Barra was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

 

15
 

 

The preliminary allocation of the purchase price in connection with the acquisition of Barra was calculated as follows:

 

Description  Fair Value   Weighted Average
Useful Life
(Years)		 
Acquired accounts receivable  $92,585      
Property, plant and equipment   8,593    7 
Right-of-use asset   122,984      
Trade names   22,000    4 
Customer relationships   550,000    10 
Agency relationships   2,585,000    10 
Developed technology   230,000    5 
Lease liability   (122,984)     
Goodwill   4,236,822    Indefinite 
   $7,725,000      

 

Trade name was measured at fair value using the relief-from-royalty method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue from the trade name, a pre-tax royalty rate of 0.5% and a discount rate of 19.5%.

 

Customer and Agency relationships were measured at fair value using the multiple-period excess earnings method under the income approach. Significant inputs used to measure the fair value include an estimate of projected revenue and costs associated with existing customers, and a discount rate of 19.5%.

 

Developed technology was measured at fair value using the cost replacement method of the cost approach. Significant inputs used to measure the fair value include an estimate of cost to replace, an obsolescence rate of 28.6%.

 

Goodwill of $4,236,822 arising from the acquisition of Barra consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Barra is currently expected to be deductible for income tax purposes. Total acquisition costs incurred through September 30, 2022 for the acquisition of Barra were $72,793 recorded as a component of General and administrative expenses.

 

The approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from April 26, 2022 to September 30, 2022 was $655,002 and a loss of $182,603, respectively.

 

Pro Forma Information

 

The results of operations of Barra will be included in the Company’s consolidated financial statements as of the date of acquisition through the current period end. The following supplemental pro forma financial information approximate combined financial information assumes that the acquisition had occurred at the beginning of the nine months ended September 30, 2022 and 2021:

 

   September 30,   September 30, 
   2022   2021 
Revenue  $13,143,889   $8,370,850 
Net Income (Loss)  $26,192,218   $(1,940,384)
Earnings (Loss) per common share, basic  $1.11   $(0.20)
Earnings (Loss) per common share, diluted  $(0.76)  $(0.20)

 

16
 

 

NOTE 3. GOODWILL AND OTHER INTANGIBLE ASSETS

 

The following table rolls forward the Company’s goodwill balance for the periods ending September 30, 2022 and December 31, 2021. As discussed in Note 1 - Prior Period Adjustments, a $(503,345) adjustment was identified for goodwill which impacted the closing December 31, 2020 balance in the same amount. Accordingly, the December 31, 2020 balance is adjusted in the following table from the originally reported balance of $9,265,070 to $8,761,725.

 

   Goodwill 
December 31, 2020  $8,761,725 
Goodwill recognized in connection with Kush acquisition on May 1, 2021  1,288,552 
December 31, 2021  10,050,277 
Goodwill recognized in connection with Medigap acquisition on January 10, 2022  19,199,008 
Goodwill recognized in connection with Barra acquisition on April 26, 2022   4,236,822 
September 30, 2022  $33,486,107 

 

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of September 30, 2022:

 SCHEDULE OF INTANGIBLE ASSETS AND WEIGHTED-AVERAGE REMAINING AMORTIZATION PERIOD

   Weighted Average Remaining Amortization period (Years)   Gross Carrying Amount   Accumulated Amortization   Net Carrying Amount 
Trade name and trademarks   4.6  $2,141,858  $(897,390)  $1,244,468
Internally developed software   4.3    1,530,537    (210,443)   1,320,094 
Customer relationships   9.3    11,922,290    (1,793,319)   10,128,971 
Purchased software   0.4    665,137    (568,039)   97,098 
Video Production Assets   0.3    50,000    (36,621)   13,379 
Non-competition agreements   2.1    3,504,810    (2,003,505)   1,501,305 
Contracts Backlog   0.3    210,000    (155,342)   54,658 
        $   20,024,632   $    (5,664,659)  $ 14,359,973 

 

The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2021:

 

   Weighted Average Remaining Amortization period (Years)  

Gross

Carrying

Amount

   Accumulated Amortization  

Net

Carrying Amount

 
Trade name and trademarks   3.5   $1,777,475   $(609,822)  $1,167,653 
Internally developed software   4.7    595,351    (28,443)   566,908 
Customer relationships   7.7    4,237,290    (1,048,726)   3,188,564 
Purchased software   0.6    562,327    (452,985)   109,342 
Video Production Assets   1.0    20,000    -    20,000 
Non-competition agreements   2.9    3,504,809    (1,478,376)   2,026,433 
             $10,697,252   $(3,618,352)  $7,078,900 

 

17
 

 

The following table reflects expected amortization expense as of September 30, 2022, for each of the following five years and thereafter:

 

    1 
Years ending December 31,   

Amortization

Expense

 
2022 (remainder of year)  $707,166  
2023   2,536,548 
2024   2,158,445 
2025   1,764,541 
2026   1,504,660 
Thereafter   5,688,613 
Total  $14,359,973  

 

NOTE 4. LONG-TERM DEBT AND SHORT-TERM FINANCINGS

 

Long-Term Debt

 

The composition of the long-term debt follows:

 

  

September 30,

2022

  

December 31,

2021

 
         
Oak Street Funding LLC Term Loan for the acquisition of EBS and USBA, net of deferred financing costs of $12,942 and $14,606 as of September 30, 2022 and December 31, 2021, respectively  $442,368   $485,317 
Oak Street Funding LLC Senior Secured Amortizing Credit Facility for the acquisition of CCS, net of deferred financing costs of $15,713 and $17,626 as of September 30, 2022 and December 31, 2021, respectively   715,816    785,826 
Oak Street Funding LLC Term Loan for the acquisition of SWMT, net of deferred financing costs of $9,613 and $11,027 as of September 30, 2022 and December 31, 2021, respectively   811,699    884,720 
Oak Street Funding LLC Term Loan for the acquisition of FIS, net of deferred financing costs of $38,298 and $42,660 as of September 30, 2022 and December 31, 2021, respectively   2,045,048    2,226,628 
Oak Street Funding LLC Term Loan for the acquisition of ABC, net of deferred financing costs of $43,749 and $48,609 as of September 30, 2022 and December 31, 2021, respectively   3,337,241    3,616,754 
Oak Street Funding LLC Term Loan for the acquisition of Barra, net of deferred financing costs of $204,958 and $0 as of September 30, 2022 and December 31, 2021, respectively   6,315,042    - 
    13,667,214    7,999,245 
Less: current portion   (1,026,541)   (913,920)
Long-term debt  $12,640,673   $7,085,325 

 

Oak Street Funding LLC – Term Loans and Credit Facilities

 

Fiscal year ending December 31, 

Maturities of

Long-Term Debt

 
2022 (remainder of year)  $211,904 
2023   1,168,585 
2024   1,482,266 
2025   1,616,891 
2026   1,760,367 
Thereafter   7,752,474 
Total   13,992,487 
Less: debt issuance costs   (325,273)
Total  $13,667,214 

 

18
 

 

Short-Term Financings

 

The Company financed certain annual insurance premiums through the use of two short-term notes, payable in nine and ten equal monthly installments of $42,894 and $4,456 at interest rates of 7.51% and 7.95%, per annum respectively. Policies financed include directors and officers and errors and omissions insurance coverage with premium financing recognized in 2022 and 2021 of $417,199 and $0, respectively. Outstanding balances as of September 30, 2022 and December 31, 2021, respectively were $309,993 and $0.

 

NOTE 5. WARRANT LIABILITIES

 

Series B Warrants

 

On December 22, 2021, the Company entered into a securities purchase agreement with several institutional buyers for the purchase and sale of (i) warrants to purchase up to an aggregate of 9,779,952 shares of the Company’s common stock, par value $0.086 per share at an exercise price of $4.09 per share, (ii) an aggregate of 2,670,892 shares of Common Stock, and (iii) 9,076 shares of the Company’s newly-designated Series B convertible preferred stock, par value $0.086 per share, with a stated value of $1,000 per share, initially convertible into an aggregate of 2,219,084 shares of Common Stock at a conversion price of $4.09 per share, each a freestanding financial instrument, (the “Private Placement”). The aggregate purchase price for the Common Shares, the Preferred Shares and the Warrants was approximately $20,000,000.

 

By entering into the Private Placement on December 22, 2021, the Company entered into a commitment to issue the Common Shares, Preferred Shares and Series B Warrants on the Initial Closing Date for a fixed price and exercise price, as applicable. The commitment to issue Series B Warrants (the “Warrant Commitment”) represents a derivative financial instrument, other than an outstanding share, that, at inception, has both of the following characteristics: (i) embodies a conditional obligation indexed to the Company’s equity. The Company classified the commitment to issue the warrants as a derivative liability because it represents a written option that does not qualify for equity accounting The Company initially measured the derivative liability at its fair value and will subsequently remeasure the derivative liability, at fair value with changes in fair value recognized in earnings. An option pricing model was utilized to calculate the fair value of the Warrant Commitment. The Company initially recorded $17,652,808 of non-operating unrealized losses within the recognition and change in fair value of warrant liabilities account for the year ended December 31, 2021. The Private Placement closed on January 4, 2022, at which time the Company remeasured the derivative liability for the warrants issued in the transaction. The Company recognized $7,726,161 and $34,621,024 of non-operating unrealized gains within the recognition and change in fair value of warrant liabilities account on the condensed consolidated statement of operations for the three and nine months ended September 30, 2022, respectively, related to the subsequent changes in its fair value through September 30, 2022. A corresponding derivative liability of $3,031,784 is included on Company’s condensed consolidated balance sheet as of September 30, 2022. The closing of the Private Placement settled the subscription receivable reported on the Company’s balance sheet as of December 31, 2021.

 

Placement Agent Warrants

 

In connection with the Private Placement, the Company issued 244,539 warrants to the placement agent for the Private Placement. The warrants were issued as compensation for the Placement Agent’s services. The Placement Agent Warrants are: (i) exercisable on any day after the six (6) month anniversary of the issue date, (ii) expire five years after the closing of the Private Placement, and (iii) exercisable at $4.09 per share. The Placement Agent Warrants contain terms that may require the Company to transfer assets to settle the warrants. Therefore, the Placement Agent Warrants are classified as a derivative liability measured at fair value of $1,525,923 on the date of issuance and will be remeasured each accounting period with the changes in fair value reported in earnings. The Placement Agent Warrants are considered financing expense fees paid to the Placement Agent. Since the financing expenses relate to a derivative liability measured at fair value, this financing expense of $1,525,923, along with non-operating unrealized gains of $193,154 and $1,450,129, were included in the recognition and change in fair value of warrant liabilities account on the condensed consolidated statement of operations for the three and nine months ended September 30, 2022, respectively, A corresponding derivative liability of $75,794 is included on Company’s condensed consolidated balance sheet as of September 30, 2022.

 

19
 

 

 

NOTE 6. EQUITY

 

Preferred Stock

 

The Company has been authorized to issue 750,000,000 shares of $0.086 par value Preferred Stock. The Board of Directors is expressly vested with the authority to divide any or all of the Preferred Stock into series and to fix and determine the relative rights and preferences of the shares of each series so established, within certain guidelines established in the Articles of Incorporation.

 

In January 2022, the Company issued 9,076 shares of its newly designated Series B convertible preferred stock through the Private Placement for the purpose of raising capital. The Series B convertible preferred stock have no voting rights and initially each share may be converted into 245 shares of the Company’s common stock. The holders of the Series B convertible preferred stock are not entitled to receive any dividends other than any dividends paid on account of the common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion limitations hereunder) to common stock which amounts shall be paid pari-passu with all holders of common stock.

 

During August 2022, all 9,076 Series B Convertible Preferred Stock were converted by third parties into 2,219,084 shares of common stock.

 

Common Stock

 

The Company has been authorized to issue 2,000,000,000 shares of common stock, $0.086 par value. Each share of issued and outstanding common stock entitles the holder thereof to fully participate in all shareholder meetings, to cast one vote on each matter with respect to which shareholders have the right to vote, and to share ratably in all dividends and other distributions declared and paid with respect to common stock, as well as in the net assets of the corporation upon liquidation or dissolution.

 

In January 2022, the Company issued 2,670,892 shares of common stock through the Private Placement for the purpose of raising capital. See Note 5 - Warrant Liabilities for proceeds received by the Company.

 

In January 2022, the Company issued 606,037 shares of common stock pursuant to the Medigap Acquisition.

 

In January 2022, upon agreement with Series A warrant holders, 375,000 warrants were exercised at a price of $6.60 into 375,000 of the Company’s common stock.

 

In March 2022, the Company issued 6,000 shares of the Company’s common stock due to the vesting of 6,000 stock awards pursuant to an employee agreement.

 

In May and June 2022, 3,276,929 Series C prepaid warrants were exchanged for 3,276,929 shares of the Company’s common stock.

 

In July 2022, 1,221,347 Series D prepaid warrants were exchanged for 1,221,347 shares of the Company’s common stock. 

 

As of September 30, 2022 and December 31, 2021, there were 18,054,469 and 10,956,109 shares of Common Stock outstanding, respectively.

 

20
 

 

Warrants

 

Series A Warrants

 

In conjunction with the Company’s initial public offering, the Company issued 2,070,000 Series A Warrants which were classified as equity warrants because of provisions, pursuant to the warrant agreement, that permit the holder obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants were recorded at a value per the offering of $0.01. The warrants may be exercised at any point from the effective date until the 5-year anniversary of issuance and are not subject to standard antidilution provisions. The Series A Warrants are exercisable at a per share exercise price equal to 110% of the public offering price of one share of common stock and accompanying Series A Warrant, $6.00. Series A warrant holders exercised 375,000 Series A warrants in January 2022, resulting in 1,695,000 of Series A warrants remaining issued and outstanding as of September 30, 2022.

 

Series C and D Warrants

 

In January 2022, as a result of the Private Placement and the Medigap Acquisition, the Company received a deficiency notification from Nasdaq indicating violation of Listing Rule 5365(a). As part of its remediation plan, in March 2022, the Company entered into Exchange Agreements with the holders of common stock issued in January 2022. Pursuant to the Exchange Agreements, the Company issued 3,276,929 Series C prepaid warrants in exchange for 3,276,929 shares of the Company’s common stock. Additionally, as compensation for entering into the Exchange Agreements, the Company issued 1,222,498 Series D prepaid warrants to the Private Placement investors for no additional consideration. The fair value of the Series D prepaid warrants was treated as a deemed dividend and accordingly treated as a reduction from income available to common stockholders in the calculation of earnings per share. Refer to Note 7, Earnings (Loss) Per Share for additional information.

 

The Series C and D Warrants are equity classified pursuant to the warrant agreement provisions that permit holders to obtain a fixed number of shares for a fixed monetary amount. The warrants are standalone equity securities that are transferable without the Company’s consent or knowledge. The warrants expire on the fifth anniversary of the respective issuance dates and are exercisable at a per share exercise price equal to $0.001.

 

In May and June 2022, the 3,276,929 Series C prepaid warrants were converted for 3,276,929 shares of the Company’s common stock for a conversion price of $0.001. Through September 30, 2022, the Company has received payments of $1,336 for these issuances.

 

In July 2022, the 1,222,498 Series D prepaid warrants were converted into 1,222,082 shares of the Company’s common stock for a conversion price of $0.001 through both cash and cashless exercises. Proceeds of $795 were received in conjunction with the cash exercise.

 

Equity-based Compensation

 

Between February and May 2022, three existing employees were awarded bonuses consisting of shares of the Company’s common stock to be vested immediately. The shares granted in 2022 were valued at $766,250 and treated as compensation expense. As of September 30, 2022, these shares have not been issued.

 

In April 2022 , pursuant to an agreement between the Company and an executive, the executive will be compensated with 60,000 shares of the Company’s common stock. These shares vest quarterly over a three-year period. The shares granted were valued at $178,200 at the date of the grant. For the three and nine months ended September 30, 2022, compensation expense on this grant was $14,850 and $25,571, respectively. As of September 30, 2022, no shares were issued under this contract.

 

Pursuant to an equity-based compensation program at one of the Company’s subsidiaries which provides agents the ability to earn and receive restricted stock awards upon completion of agreed upon service requirements, the Company granted 303,143 restricted stock awards which were immediately vested. Stocks earned are restricted for twelve months. The stocks were valued at $249,650 and recognized as stock-based compensation for the three and nine months ended September 30, 2022.

 

NOTE 7. EARNINGS (LOSS) PER SHARE

 

Basic earnings per common share (“EPS”) applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted-average number of common shares outstanding.

 

If there is a loss from operations, diluted EPS is computed in the same manner as basic EPS is computed. Similarly, if the Company has net income but its preferred dividend adjustment made in computing income available to common stockholders results in a net loss available to common stockholders, diluted EPS would be computed in the same manner as basic EPS.

 

21
 

 

The following calculates basic and diluted EPS:

 

   Three Months   Three Months 
   ended   ended 
   September 30,
2022		   September 30,
2021		 
Net income (loss)  $6,122,093   $(595,233)
Deemed dividend   

-

    - 
Net income (loss), numerator, basic computation   

6,122,093

    (595,233)
Recognition and change in fair value of Series B warrant liability   

(7,726,161

)   - 
Recognition and change in fair value of Placement Agent warrant liability   (193,154)     
Net income (loss), numerator, diluted computation  $

(1,797,222

)  $(595,233)
           
Weighted average common shares   16,491,942    10,944,439 
Effect of series C warrants   

- 

    - 
Effect of Series D warrants   623,285    - 
Effect of weighted average vested stock awards   

309,040

      
Weighted average shares - denominator basic computation   17,424,267    10,944,439 
Effect of dilutive securities   

-

    - 
Weighted average shares, as adjusted - denominator diluted computation   17,424,267    10,944,439 
Earnings (loss) per common share – basic  $

0.35

   $(0.05)
Earnings (loss) per common share – diluted   

(0.10

)   (0.05)

 

   Nine Months   Nine Months 
   ended   ended 
   September 30,
2022		   September 30,
2021		 
Net income (loss)  $25,957,785   $(2,486,045)
Deemed dividend   (6,930,335)   - 
Net income (loss), numerator, basic computation   19,027,450    (2,486,045)
Recognition and change in fair value of Series B warrant liability   (32,474,324)     
Net income (loss), numerator, diluted computation  $

(13,446,874

)  $(2,486,045)
           
Weighted average shares   14,308,069    9,809,092 
Effect of series C warrants   

1,819,213

      
Effect of Series D warrants   1,019,803    - 
Effect of weighted average vested stock awards   

173,061

    - 
Weighted average shares - denominator basic computation   

17,320,146

    9,809,092 
Effect of dilutive securities   

-

    

-

 
Weighted average shares, as adjusted - denominator diluted computation   17,320,146   9,809,092 
Earnings (loss) per common share - basic  $1.10  $(0.25)
Earnings (loss) per common share - diluted  $(0.78)  $(0.25)

 

The gain in fair value of the Series B warrants for the three and nine months September 30, 2022 is included in the numerator of the dilutive EPS calculation to eliminate the effects of the warrants that have been recorded in net income as the impact is dilutive. The gain in fair value of the Placement Agent warrants for the three months September 30, 2022 is included in the numerator of the dilutive EPS calculation to eliminate the effects of the warrants that have been recorded in net income as the impact is dilutive. For the nine months ended September 30, 2022, as the fair value change in the Placement Agent warrants is a loss, the addback of the loss would result in anti-dilution and therefore is not included in the numerator of dilutive EPS.

 

The potential impact of the 9,779,950 and 244,539 Series B and Placement Agent warrants are excluded from the denominator of the dilutive EPS calculation for the three and nine months ended September 30, 2022 as the average market price for both periods does not exceed the exercise price of the warrants, resulting in anti-dilutive securities.

 

Additionally, the following are considered anti-dilutive securities excluded from weighted-average shares used to calculate diluted net loss per common share:

 

    1    2 
   For the three months ended 
   September 30,
2022		   September 30,
2021		 
Shares subject to outstanding common stock options   

163,925

    

163,925

 
Shares subject to outstanding Series A warrants   1,695,000    2,070,000 
Shares subject to preferred stock   

2,219,084

    

11,670

 
Shares subject to unvested stock awards   

61,280

    

15,655

 

 

    1    2 
   For the nine months ended 
   September 30,
2022		   September 30,
2021		 
Shares subject to outstanding common stock options   

163,925

    

163,925

 
Shares subject to outstanding Series A warrants   1,695,000    2,070,000 
Shares subject to outstanding Placement Agent warrants   

244,539

    - 
Shares subject to preferred stock   

2,219,084

    

11,670

 
Shares subject to unvested stock awards   

61,280

    

15,655

 

  

22
 

  

NOTE 8. LEASES

 

Operating lease expense for the three months ended September 30, 2022 and 2021 was $159,624 and $97,265 respectively. Operating lease expense for the nine months ended September 30, 2022 and 2021 was $434,798 and $220,798 respectively. As of September 30, 2022, the weighted average remaining lease term and weighted average discount rate for the operating leases were 3.86 years and 5.72% respectively.

 

Future minimum lease payment under these operating leases consisted of the following:

 

Year ending December 31, 

Operating Lease

Obligations

 
2022  $157,633 
2023   570,275 
2024   269,908 
2025   144,124 
2026   113,738 
Thereafter   268,202 
Total undiscounted operating lease payments   1,523,880 
Less: Imputed interest   152,467 
Present value of operating lease liabilities  $1,371,413 

 

NOTE 9. COMMITMENTS AND CONTINGENCIES

 

Legal Contingencies

 

The Company is subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, no legal contingencies are accrued as of September 30, 2022 and December 31, 2021. Litigation relating to the insurance brokerage industry is not uncommon. As such the Company, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.

 

Earn-out liabilities

 

The following outlines changes to the Company’s earn-out liability balances for the respective periods ended September 30, 2022 and December 31, 2021:

 

    Fortman   Montana   Altruis   Kush   Barra   Total 
Ending balance December 31, 2021   $515,308   $615,969   $992,868   $1,689,733   $-   $3,813,878 
Changes due to acquisitions    -    -    -    -    600,000    600,000 
Changes due to payments    (34,430)   (326,935)   (84,473)   (1,181,458)   -    (1,627,296)
Changes due to fair value adjustments    186,122    37,741    (212,609)   201,191    (80,000)   132,445
Ending balance September 30, 2022   $667,000   $326,775   $695,786   $

709,466

   $520,000   $2,919,027 

 

    CCS     Fortman     Montana     Altruis     Kush     Total  
Ending balance December 31, 2020   $ 81,368     $ 432,655     $ 522,553     $ 1,894,842     $ -     $ 2,931,418  
Changes due to business combinations     -       -       -       -       1,694,166       1,694,166  
Changes due to payments     -       -       -       (452,236 )     -       (452,236 )
Changes due to fair value adjustments     -       82,653       93,416       (449,738 )     (4,433 )     (278,102 )
Changes due to write-offs     (81,368 )     -       -       -       -       (81,368 )
Ending balance December 31, 2021   $ -     $ 515,308     $ 615,969     $ 992,868     $ 1,689,733     $ 3,813,878  

 

NOTE 10. RELATED PARTY TRANSACTIONS

 

On September 13, 2022, the Company issued a promissory note to YES Americana Group, LLC, a related party entity for the principal sum of $1,500,000 (the “Note”). The Note matures on January 15, 2024, bearing interest of 0% per annum for the first six months, and 5% per annum thereafter, payable monthly. In the event the Note is not paid by the maturity date, the loan will automatically be extended for an additional year until January 15, 2025, and if necessary, extended again for one additional year through January 15, 2026.

 

23
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Overview

 

Reliance Global Group, Inc. (formerly known as Ethos Media Network, Inc.) was incorporated in Florida on August 2, 2013. In September 2018, Reliance Global Holdings, LLC, a related party, purchased a controlling interest in the Company. Ethos Media Network, Inc. was renamed Reliance Global Group, Inc. on October 18, 2018.

 

We operate as a diversified company engaging in business in the insurance market, as well as other related sectors. Our focus is to grow the Company by pursuing an aggressive acquisition strategy, initially and primarily focused upon wholesale and retail insurance agencies. The Company is controlled by the same management team as Reliance Global Holdings, LLC (“Reliance Holdings”), a New York based firm that is the owner and operator of numerous companies with core interests in real estate and insurance. Our relationship with Reliance Holdings provides us with significant benefits: (1) experience, knowledge, and industry relations; (2) a source of acquisition targets currently under Reliance Holdings’ control; and (3) financial and logistics assistance. We are led and advised by a management team that offers over 100 years of combined business expertise in real estate, insurance, and the financial service industry.

 

In the insurance sector, our management has extensive experience acquiring and managing insurance portfolios in several states, as well as developing specialized programs targeting niche markets. Our primary strategy is to identify specific risk to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows.

 

As part of our growth and acquisition strategy, we continue to survey the current insurance market for value-add acquisition opportunities. As of September 30, 2022, we have acquired ten insurance agencies, including both affiliated and unaffiliated companies and long term, we seek to conduct all transactions and acquisitions through our direct operations.

 

Over the next 12 months, we plan to focus on the expansion and growth of our business through continued asset acquisitions in insurance markets and organic growth of our current insurance operations through geographic expansion and market share growth.

 

Further, we launched our 5MinuteInsure.com (“5MI”) Insurtech platform during 2021 which expanded our national footprint. 5MI is a high-tech proprietary tool developed by us as a business to consumer portal which enables consumers to instantly compare quotes from multiple carriers and purchase their car and home insurance in a time efficient and effective manner. 5MI taps into the growing number of online shoppers and utilizes advanced artificial intelligence and data mining techniques, to provide competitive insurance quotes in around 5 minutes with minimal data input needed from the consumer. The platform launched during the summer of 2021 and currently operates in 46 states offering coverage with up to 30 highly rated insurance carriers.

 

With the acquisition of Barra, we launched RELI Exchange, our business-to-business (B2B) InsurTech platform and agency partner network that builds on the artificial intelligence and data mining backbone of 5MinuteInsure.com. Through RELI Exchange we on-board agency partners and provide them an InsurTech platform white labeled, designed and branded specifically for their business. This combines the best of digital and human capabilities by providing our agency partners and their customers quotes from multiple carriers within minutes. Since its inception, RELI Exchange, has increased its agent roster by more than 30%.

 

Business Trends and Uncertainties

 

The insurance intermediary business is highly competitive, and we actively compete with numerous firms for customers, properties and insurance companies, many of which have relationships with insurance companies, or have a significant presence in niche insurance markets that may give them an advantage over us. Other competitive concerns may include the quality of our products and services, our pricing and the ability of some of our customers to self-insure and the entrance of technology companies into the insurance intermediary business. A number of insurance companies are engaged in the direct sale of insurance, primarily to individuals, and do not pay commissions to agents and brokers.

 

24
 

 

Financial Instruments

 

The Company’s financial instruments as of September 30, 2022, consist of derivative warrants. These are accounted at fair value as of inception/issuance date, and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, (non-cash) gain or loss.

 

Insurance Operations

 

Our insurance operations focus on the acquisition and management of insurance agencies throughout the U.S. Our primary focus is to pinpoint undervalued wholesale and retail insurance agencies with operations in growing or underserved segments (including healthcare and Medicare, as well as personal and commercial insurance lines). We then focus on expanding their operations on a national platform and improving operational efficiencies in order to achieve asset value appreciation while generating interim cash flows. In the insurance sector, our management team has over 100 years of experiences acquiring and managing insurance portfolios in several states, as well as developing specialized programs targeting niche markets. We plan to accomplish these objectives by acquiring wholesale and retail insurance agencies it deems to represent a good buying opportunity (as opposed to insurance carriers) as insurance agencies bear no insurance risk. Once acquired, we plan to develop them on a national platform to increase revenues and profits through a synergetic structure. The Company is initially focused on segments that are underserved or growing, including healthcare and Medicare, as well as personal and commercial insurance lines.

 

Insurance Acquisitions and Strategic Activities

 

As of the balance sheet date, we have acquired ten insurance brokerages (see table below), including both acquisitions of affiliated companies (i.e., owned by Reliance Holdings before the acquisition) and unaffiliated companies. As our acquisition strategy continues, our reach within the insurance arena can provide us with the ability to offer lower rates, which could boost our competitive position within the industry.

 

Acquired   Date   Location   Line of Business   Status
                 
U.S. Benefits Alliance, LLC (USBA)   October 24, 2018   Michigan   Health Insurance   Affiliated
                 
Employee Benefit Solutions, LLC (EBS)   October 24, 2018   Michigan   Health Insurance   Affiliated
                 
Commercial Solutions of Insurance Agency, LLC (CCS or Commercial Solutions)   December 1, 2018   New Jersey   P&C – Trucking Industry   Unaffiliated
                 
Southwestern Montana Insurance Center, Inc. (Southwestern Montana or Montana)   April 1, 2019   Montana   Group Health Insurance   Unaffiliated
                 
Fortman Insurance Agency, LLC (Fortman or Fortman Insurance)   May 1, 2019   Ohio  

P&C and

Health Insurance

   Unaffiliated
                 
Altruis Benefits Consultants, Inc. (Altruis)   September 1, 2019   Michigan   Health Insurance   Unaffiliated
                 
UIS Agency, LLC (UIS)   August 17, 2020   New York   Health Insurance   Unaffiliated
                 
J.P. Kush and Associates, Inc. (Kush)   May 1, 2021   Michigan   Health Insurance   Unaffiliated
                 
Medigap Healthcare Insurance Agency, LLC (Medigap)   January 10, 2022   Florida   Health Insurance   Unaffiliated
                 
Barra & Associates, LLC   April 26, 2022   Illinois   Health Insurance   Unaffiliated

 

25
 

 

J.P. Kush and Associates, Inc. Transaction

 

On May 1, 2021, we entered into a Purchase Agreement with J.P. Kush and Associates, Inc. whereby we purchased the business and certain assets noted within the Purchase Agreement (the “Kush Acquisition”) for a total purchase price of $3,644,166. The purchase price was paid with a cash payment of $1,900,000, $50,000 in restricted shares of our common stock, in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and an earn-out payment.

 

The Kush Acquisition was accounted for as a business combination in accordance with the acquisition method under the guidance in ASC 805-10 and 805-20. Accordingly, the total purchase consideration was allocated to intangible assets acquired based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

 

The allocation of the purchase price in connection with the Kush Acquisition was calculated as follows:

 

Description  Fair Value  

Weighted Average

Useful Life

(Years)

 
Accounts receivable  $291,414      
Trade name and trademarks   685,400    5 
Customer relationships   551,000    10 
Non-competition agreements   827,800    5 
Goodwill   1,288,552    Indefinite 
   $3,644,166      

 

Goodwill of $1,288,552 arising from the Kush Acquisition consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the Kush Acquisition is currently expected to be deductible for income tax purposes. Total acquisition costs for the Kush Acquisition incurred were $58,092 recorded as a component of General and administrative expenses. The approximate revenue and net profit for the acquired business as a standalone entity per ASC 805 from January 1, 2021 to April 30, 2021 was $380,349 and $166,667, respectively, and from January 1, 2020 to December 31, 2020, $1,141,047 and $500,000, respectively.

 

Medigap Healthcare Insurance Agency, LLC Transaction

 

On January 10, 2022, pursuant to an asset purchase agreement, dated December 21, 2021, we completed the acquisition of all of the assets of Medigap Healthcare Insurance Company, LLC (“Medigap”) for a purchase price of $20,096,250 consisting of: (i) payment to Medigap of $18,138,750 in cash and (ii) the issuance to Medigap of 606,037 shares of the Company’s restricted common stock in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties. The shares issued to Medigap as part of the purchase price are subject to lock up arrangements pursuant to which 50% of the shares may be sold after the one-year anniversary of the date of closing of the transaction and the balance of the shares may be sold after the second-year anniversary of the date of closing of the transaction.

 

The acquisition of Medigap was accounted for as a business combination in accordance with the acquisition method under the guidance in ASC 805-10 and 805-20. Accordingly, the total purchase consideration was allocated to intangible assets acquired based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

 

26
 

 

The allocation of the purchase price in connection with the acquisition of Medigap was calculated as follows:

 

Description  Fair Value   Weighted Average
Useful Life
(Years)		 
Property, plant and equipment  $20,666    6 
Right-of-use asset   317,787      
Trade name and trademarks   340,000    15 
Customer relationships   4,550,000    12 
Technology   67,000    3 
Backlog   210,000    1 
Chargeback reserve   (1,484,473)     
Lease liability   (317,787)     
Goodwill   19,199,008    Indefinite 
   $22,902,201      

 

Goodwill of $19,199,008 arising from the acquisition of Medigap consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Medigap is currently expected to be deductible for income tax purposes. Total acquisition costs for the acquisition of Medigap incurred were $94,065 recorded as a component of General and administrative expenses. The approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from January 10, 2022 to September 30, 2022 was $3,868,654 and a loss of $693,861, respectively.

 

Barra & Associates, LLC Transaction

 

On April 26, 2022, we entered into an asset purchase agreement (the “APA”) with Barra & Associates, LLC (“Barra”) pursuant to which the Company purchased all of the assets of Barra & Associates, LLC on April 26, 2022 for a purchase price in the amount of $7,725,000 in cash, with $6,000,000 paid to Barra at closing, $1,125,000 payable in nine months from closing, and a final earnout of $600,000 payable over two years from closing based upon meeting stated milestones. The APA contains standard, commercial representations and warranties and covenants. The source of the cash payment was $6,520,000 in funds borrowed from Oak Street Lending (“Loan”), our existing lender pursuant to a Fifth Amendment to Credit Agreement and Promissory Note, of even date. The purchase price is subject to post-closing adjustment to reconcile certain pre-closing credits and liabilities of the parties.

 

The acquisition of Barra was accounted for as a business combination in accordance with the acquisition method pursuant to FASB Topic No. 805, Business Combination (ASC 805). Accordingly, the total purchase consideration was allocated to the assets acquired, and liabilities assumed based on their respective estimated fair values. The acquisition method of accounting requires, among other things, that assets acquired, and liabilities assumed, if any, in a business purchase combination be recognized at their fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets requires the use of significant estimates and assumptions, including estimating future cash flows, developing appropriate discount rates, estimating the costs, and timing.

 

27
 

 

The preliminary allocation of the purchase price in connection with the acquisition of Medigap was calculated as follows:

 

Description  Fair Value  

Weighted

Average Useful

Life (Years)

 
Acquired accounts receivable  $92,585      
Property, plant and equipment   8,593    7 
Right-of-use asset   122,984      
Trade names   22,000    4 
Customer relationships   550,000    10 
Developed technology   230,000    5 
Agency relationships   2,585,000    10 
Lease liability   (122,984)     
Goodwill   4,236,822    Indefinite 
   $7,725,000      

 

Goodwill of $4,236,822 arising from the acquisition of Barra consisted of the value of the employee workforce and the residual value after all identifiable intangible assets were valued. Goodwill recognized pursuant to the acquisition of Barra is currently expected to be deductible for income tax purposes. Total acquisition costs incurred through September 30, 2022 for the acquisition of Barra were 72,793 recorded as a component of General and administrative expenses.

 

The approximate revenue and net profit or loss for the acquired business as a standalone entity per ASC 805 from April 26, 2022 to September 30, 2022 was $655,002 and a loss of $182,603, respectively.

 

Recent Developments

 

Private Placement

 

On December 22, 2021, we entered into a securities purchase agreement with several institutional buyers for the purchase and sale of (i) warrants to purchase up to an aggregate of 9,779,952 shares of the Company’s common stock, par value $0.086 per share at an exercise price of $4.09 per share, (ii) an aggregate of 2,670,892 shares of Common Stock, and (iii) 9,076 shares of the Company’s newly-designated Series B convertible preferred stock, par value $0.086 per share, with a stated value of $1,000 per share, initially convertible into an aggregate of 2,219,084 shares of Common Stock at a conversion price of $4.09 per share in a private placement (the “Private Placement”).

 

On January 5, 2022, pursuant to the securities purchase agreement dated December 22, 2021, the Private Placement was closed. The Private Placement resulted in aggregate gross proceeds to us of approximately $20,000,000, before deducting placement agent fees and other offering expenses payable by us. The Warrants are exercisable upon issuance and will expire five years from the date of issuance. In connection with the Private Placement, we issued to the placement agent warrants to purchase 244,539 shares of the Company’s Common Stock at an exercise price of $4.09 per share (the “Placement Agent Warrants”). The Placement Agent Warrants have substantially the same terms as the Warrants issued in the Private Placement.

 

During August 2022, all 9,076 Series B Convertible Preferred Stock were converted by third parties into 2,219,084 shares of common stock.

 

Nasdaq Notification and Warrant Exchange

 

On January 31, 2022, we received a deficiency notification from Nasdaq regarding the issuance of shares in the Medigap Acquisition and Private Placement in violation of Listing Rule 5635(a). This rule requires an issuer to obtain shareholder approval with respect to an acquisition paid for from the proceeds of a sale of common stock of the issuer which equals or exceeds 20% of the shares of the issuer, issued and outstanding prior to the acquisition. The Company submitted a remediation plan under which the Nasdaq granted us an extension to implement the required changes until May 10, 2022.

 

28
 

 

As part of its remediation plan, on March 22, 2022 we entered into Exchange Agreements with the holders of common stock issued in January 2022 resulting from the Medigap Acquisition and Private Placement. Pursuant to the Exchange Agreements, we issued 3,276,929 Series C prepaid warrants in exchange for 3,276,929 shares of our common stock that were previously issued. Additionally, to compensate the Private Placement investors for entering into the Exchange Agreements, we issued 1,222,498 Series D prepaid warrants to such investors for no additional consideration on the same date. The fair value of the Series D prepaid warrants upon issuance was $6,930,335; such amount was treated as a deemed dividend and accordingly reduced income available to common stockholders for the period. Shares of common stock underlying the Series C and D prepaid warrants are treated as outstanding for purposes of calculating basic and diluted earnings per share. The Series C warrants were exercised during the quarter ended June 30, 2022. The Series D warrants were exercised during the quarter ended September 30, 2022.

 

Stock Split

 

On January 21, 2021 we effected a reverse split of the issued and outstanding shares of common stock in a ratio of 1:85.71 which simultaneously occurred with the Company’s uplisting to the Nasdaq Capital Market. The Company has adjusted all of share and per share numbers to take into account this reverse stock split.

 

Results of Operations

 

Comparison of the three months ended September 30, 2022 to the three months ended September 30, 2021

 

The following table sets forth our revenue and operating expenses for each of the years presented.

 

   September 30,
2022		   September 30,
2021		 
Revenue          
Commission income  $4,153,361   $2,581,636 
Total revenue   4,153,361    2,581,636 
           
Operating expenses          
Commission expense   862,857    660,708 
Salaries and wages   

2,114,730

    1,188,267 
General and administrative expenses   1,253,097    755,130 
Marketing and advertising   726,115    65,010 
Depreciation and amortization   713,444    387,729 
Total operating expenses   5,670,243    3,056,844 
           
Loss from operations   

(1,516,882

)   (475,208)
           
Other expense, net   7,638,975    (120,025)
           
Total Other income (expense)   7,638,975    (120,025)
           
Net income (loss)   6,122,093    (595,233)

 

Revenues

 

The Company’s revenue is primarily comprised of commission paid by health insurance carriers or their representatives related to insurance plans that have been purchased by a member who used our services. We define a member as an individual currently covered by an insurance plan, including individual and family, Medicare-related, small business, and ancillary plans, for which the Company is entitled to receive compensation from an insurance carrier.

 

29
 

 

We had revenues of $4.2 million for the three months ended September 30, 2022, as compared to $2.6 million for the three months ended September 30, 2021. The increase of $1.6 million or 61% is primarily driven by organic growth and the additional insurance agencies acquired in 2022.

 

Commission expense

 

We had total commission expense of $863,000 for the three months ended September 30, 2022 compared to $661,000 for the three months ended September 30, 2021. The increase of $202,000 or 31% is primarily driven by organic growth and the additional insurance agencies acquired in 2022.

 

Salaries and wages

 

We reported $2.1 million of salaries and wages expense for the three months ended September 30, 2022 compared to $1.2 million for the three months ended September 30, 2021. The increase of $926,000 or 78% is a result of the Company’s growth driven by expanded operations, both organic and due to the additional insurance agencies acquired in 2022.

 

General and administrative expenses

 

We had total general and administrative expenses of $1.3 million for the three months ended September 30, 2022, as compared to $755,000 for the three months ended September 30, 2021. The increase in expense of $498,000 or 66% is a result of the Company’s growth driven by expanded operations, both organic and due to the additional insurance agencies acquired in 2022.

 

Marketing and advertising

 

We reported $726,000 of marketing and advertising expense for the three months ended September 30, 2022 compared to $65,000 for the three months ended September 30, 2021. The increase of $661,000 or 1,017% is primarily a result of Medigap’s direct business to consumer marketing model deployed through social media platforms, in addition to overall increased branding and outreach efforts to achieve greater industry presence.

 

Depreciation and amortization

 

We reported $713,000 of depreciation and amortization expense for the three months ended September 30, 2022 compared to $388,000 for the three months ended September 30, 2021. The increase of $326,000 or 84% is primarily a result of our acquired tangible and intangible assets through business combinations.

 

Other income and expense

 

We reported $7.6 million of other income for the three months ended September 30, 2022 compared to $120,000 of other expense for the three months ended September 30, 2021. The increase of $7.8 million or 6,464% is attributable primarily to the change in fair value of warrant liabilities of $7.9 million driven by various factors including the Company’s stock price as of the period close, offset by interest expense.

 

30
 

 

Comparison of the Nine months ended September 30, 2022 to the Nine months ended September 30, 2021

 

The following table sets forth our revenue and operating expenses for each of the periods presented.

 

   September 30,
2022		   September 30,
2021		 
Revenue          
Commission income  $12,596,268   $7,096,213 
Total revenue   12,596,268    7,096,213 
           
Operating expenses          
Commission expense   

2,617,140

    1,748,451 
Salaries and wages   

6,373,697

    3,217,441 
General and administrative expenses   

5,465,384

    2,961,881 
Marketing and advertising   1,922,520    143,110 
Depreciation and amortization   

2,077,372

    1,090,183 
Total operating expenses   

18,456,113

    9,161,066 
           
Loss from operations   (5,859,845)   (2,064,853)
           
Total Other income (expense)   31,817,630    (421,192)
           
Net income (loss)  $25,957,785   $(2,486,045)

 

Revenues

 

We had revenues of $12.6 million for the nine months ended September 30, 2022, as compared to $7.1 for the nine months ended September 30, 2021. The increase of $5.5 million or 78% is primarily driven by organic growth and the additional insurance agencies acquired in 2022.

 

Commission expense

 

We had total commission expense of $2.6 million for the nine months ended September 30, 2022 compared to $1.7 million for the nine months ended September 30, 2021. The increase of $0.9 million or 50% is primarily driven by organic growth and the additional insurance agencies acquired in 2022.

 

Salaries and wages

 

We reported $6.4 million of salaries and wages expense for the nine months ended September 30, 2022 compared to $3.2 million for the nine months ended September 30, 2021. The increase of $3.2 million or 98% is primarily driven by expanded operations, both organic and due to the additional insurance agencies acquired in 2022.

 

General and administrative expenses

 

We had total general and administrative expenses of $5.5 million for the nine months ended September 30, 2022, as compared to $3.0 million for the nine months ended September 30, 2021. The increase in expense of $2.5 million or 85% is primarily driven by expanded operations, both organic and due to the additional insurance agencies acquired in 2022.

 

31
 

 

Marketing and advertising

 

We reported $1.9 million of marketing and advertising expense for the nine months ended September 30, 2022 compared to $143,000 for the nine months ended September 30, 2021. The increase of $1.8 million or 1,243% is primarily a result of Medigap’s direct business to consumer marketing model deployed through social media platforms, in addition to overall increased branding and outreach efforts to achieve greater industry presence.

 

Depreciation and amortization

 

We reported $2.1 million of depreciation and amortization expense for the nine months ended September 30, 2022 compared to $1.1 million for the nine months ended September 30, 2021. The increase of $1.0 million or 91% is a result of the assets we acquired through business combinations.

 

Other income and expense

 

We reported $31.8 million of other income for the nine months ended September 30, 2022 compared to a loss of $421,000 for the nine months ended September 30, 2021. The increase of $32.2 million or 7,654% is attributable primarily to the recognition and change in fair value of warrant liabilities of $32.4 million driven by various factors including the Company’s stock price as of the period close, offset by interest expense.

 

Liquidity and capital resources

 

As of September 30, 2022, we had a cash balance of $3.0 million and a working capital deficit of $3.5 million compared with a cash balance of $4.6 million and working capital deficit of $37 million at December 31, 2021. The increase in working capital is primarily attributable to the issuance of the derivative warrant liability commitments, effectively reclassifying them from current to non-current liabilities.

 

The spread of the coronavirus (COVID-19) outbreak in the United States has resulted in economic uncertainties which may negatively impact our business operations. While the disruption is expected to be temporary, there is uncertainty surrounding the duration and extent of the impact. Currently we have not seen any material financial impact as a result of the coronavirus outbreak. However, management is actively monitoring the global situation on its financial condition, liquidity, operations, industry and workforce.

 

Adverse events such as health-related concerns about working in our offices, the inability to travel and other matters affecting the general work environment could harm our business and our business strategy. While we do not anticipate any material impact to our business operations as a result of the coronavirus, in the event of a major disruption caused by the outbreak of pandemic diseases such as coronavirus, we may lose the services of our employees or experience system interruptions, which could lead to diminishment of our business operations. Any of the foregoing could harm our business and delay the implementation of our business strategy and we cannot anticipate all the ways in which the current global health crisis and financial market conditions could adversely impact our business.

 

Inflation

 

The Company generally may be impacted by rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits, and facility leases. The Company believes inflation could have a material impact to pricing and operating expenses in future periods due to the state of the economy and current inflation rates.

 

Off-balance sheet arrangements

 

We do not have any off-balance sheet arrangements as such term is defined in Regulation S-K.

 

Cash Flows

 

  

Nine Months Ended

September 30,

 
   2022   2021 
Net cash used in operating activities  $(2,177,998)  $(1,304,320)
Net cash used in investing activities   (24,982,609)   (1,963,897)
Net cash provided by financing activities   25,564,501    8,878,110 
Net (decrease) increase in cash, cash equivalents, and restricted cash  $(1,596,106)  $5,609,893 

 

32
 

 

Operating Activities

 

Net cash used in operating activities for the nine months ended September 30, 2022 was $2.2 million, which includes net income of $26.0 million offset by non-cash income of $28.9 million principally related to recognition and change in fair value of warrant liabilities of $32.4 million, offset by an earn-out fair value adjustment of $132,445, share based compensation expense of $1.2 million, and depreciation and amortization of $2.1 million, as well as changes of net working capital items in the amount of $760,000 principally due to a decrease in accounts receivable of $92,000, a decrease in prepaid expense and other current assets of $2.3 million, an increase in other payables of $35,000, offset by decreases in accounts payable and accrued expenses of $1.5 million and decrease of the chargeback reserve of $134,000.

 

Investing Activities

 

During the nine months ended September 30, 2022, cash flows used in investing activities were $25.0 million compared to cash flow used in investing activities of $2.0 million for the nine months ended September 30, 2021. The cash used relates to cash paid for the acquisition of Medigap and Barra of $24.1 million, the purchase of property and equipment of $68,000 and cash paid of $776,000 for intangible assets.

 

Financing Activities

 

During the nine months ended September 30, 2022, cash provided by financing activities was $25.6 million as compared to $8.9 million for the nine months ended September 30, 2021. The net cash provided by financing activities is primarily related to proceeds from the Private Placement offering in January 2022. The net proceeds from the issuance of these shares was $17.9 million. Additionally, we received proceeds of $2.5 million from the exercise of Series A warrants, $6.5 million through loan proceeds received for a business acquisition and $1.5 million through a related party loan. These were offset by debt principal repayments of $663,000, payment of debt issuance costs of $214,000, payment of a related party loan of $174,000, payments on the earn out liability of $1.6 million and short term financing of $107,000.

 

Significant Accounting Policies and Estimates

 

We describe our significant accounting policies in Note 2, Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements, and our critical accounting estimates in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. There have been no significant changes in our significant accounting policies or critical accounting estimates since the end of fiscal year 2021.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2022. Based on the evaluation, management has concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2022.

 

Changes in Internal Control over Financial Reporting

 

There have not been any changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter which is the subject of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II

 

Item 1. Legal Proceedings.

 

We are subject to various legal proceedings and claims, either asserted or unasserted, arising in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe the outcome of any of these matters will have a material adverse effect on our business, financial position, results of operations, or cash flows, and accordingly, no legal contingencies are accrued as of September 30, 2022. Litigation relating to the insurance brokerage industry is not uncommon. As such we, from time to time have been, subject to such litigation. No assurances can be given with respect to the extent or outcome of any such litigation in the future.

 

33
 

 

Item 1A. Risk Factors.

 

Investing in our common stock involves a high degree of risk. You should consider carefully the information disclosed in Part I, Item1A, “Risk Factors,” contained in our Annual Report on Form 10-K for the year ended December 31, 2021. Except as set forth below, there have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.

 

Our shares of common stock are currently listed on The Nasdaq Capital Market. If we fail to satisfy the continued listing requirements of The Nasdaq Capital Market, such as the corporate governance requirements, minimum bid price requirement or the minimum stockholder’s equity requirement, The Nasdaq Stock Market LLC may take steps to delist our common stock. Any delisting would likely have a negative effect on the price of our common stock and would impair stockholders’ ability to sell or purchase their common stock when they wish to do so.

 

On September 27, 2022, we received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying us that for the preceding 30 consecutive business days (August 15, 2022 through September 26, 2022), our common stock did not maintain a minimum closing bid price of $1.00 per share (“Minimum Bid Price Requirement”) as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of our common stock which will continue to trade on The Nasdaq Capital Market under the symbol “RELI”. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we initially have a compliance period of 180 calendar days, or until March 27, 2023, to regain compliance with Nasdaq Listing Rules. Compliance can be achieved automatically and without further action if the closing bid price of our common stock is at or above $1.00 for a minimum of ten consecutive business days at any time during the compliance period, in which case Nasdaq will notify us of our compliance and the matter will be closed. If, however, we do not achieve compliance with the Minimum Bid Price Requirement by March 27, 2023, we may be eligible for additional time to comply; however, such additional time is not guaranteed and is subject to the discretion of Nasdaq. In order to be eligible for such additional time, we will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and must notify Nasdaq in writing of our intention to cure the deficiency during the second compliance period

 

We intend to attempt to take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any action taken by us would result in our common stock meeting The Nasdaq listing requirements, or that any such action would stabilize the market price or improve the liquidity of our common stock. Any perception that we may not regain compliance or a delisting of our common stock by Nasdaq could adversely affect our ability to attract new investors, decrease the liquidity of the outstanding shares of our common stock, reduce the price at which such shares trade and increase the transaction costs inherent in trading such shares with overall negative effects for our stockholder. In addition, delisting of our common stock from Nasdaq could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, and might deter certain institutions and persons from investing in our common stock.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None that have not been previously disclosed in our filings with the SEC.

 

Item 3. Defaults Upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Not applicable.

 

Item 6. Exhibits

 

The following exhibits are filed with this Form 10-K.

 

Exhibit No.   Description
     

3.1

   Articles of Incorporation of Issuer (incorporated by reference to exhibit 3.1 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     

3.2

   Bylaws of Issuer (incorporated by reference to exhibit 3.2 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     

3.3

   Articles of Formation of Southwestern Montana Insurance Center, LLC(incorporated by reference to exhibit 3.3 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     

3.4

   Certificate of Formation of Commercial Coverage Solutions LLC(incorporated by reference to exhibit 3.4 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     

3.5

   Articles of Organization of Employee Benefits Solutions, LLC(incorporated by reference to exhibit 3.5 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     

3.6

   Articles of Organization of Fortman Insurance Solutions, LLC (incorporated by reference to exhibit 3.6 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     

3.7

   Articles of Organization of US Benefits Alliance, LLC (incorporated by reference to exhibit 3.7 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     

3.8

   Articles of Incorporation of Altruis Benefits Corporation (incorporated by reference to exhibit 3.8 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     

3.9

   Articles of Incorporation of Kush Benefit Solutions, LLC Corporation (incorporated by reference to exhibit 3.9 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     

3.10

   Articles of Amendment to the Articles of Incorporation (incorporated by reference to exhibit 3.9 to Amendment No.4 to the Registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on February 5, 2021)(File Number 333-249381))

 

34
 

 

3.11

   Amendment to Articles of Incorporation(incorporated by reference to exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 6, 2022 (File Number 001-40020))
     

3.12

   Medigap Healthcare Insurance Agency LLC Formation and Assignment Documents(incorporated by reference to exhibit 3.11 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2021 (File Number 001-40020))
     
3.13   Articles of Organization of RELI Exchange, LLC
     
4.1*  

YES Americanna LLC Promissory Note

     
31.1*   Certification of Chief Executive Officer pursuant to Section302 of the Sarbanes-Oxley Act 2002*
     
31.2*   Certification of Chief Financial Officer pursuant to Section302 of the Sarbanes-Oxley Act 2002*
     
32.1*   Section 1350 Certification of the Chief Executive Officer and Chief Financial Officer*
     
32.2*   Section 1350 Certification of the Chief Financial Officer and Chief Financial Officer*
101.INS*   Inline XBRL Instance Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).

 

*Filed herewith

 

35
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act, the registrant has duly caused this Form 10-Q statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lakewood, State of New Jersey on November 14, 2022.

 

Reliance Global Group, Inc.  
     
By: /s/ Ezra Beyman  
  Ezra Beyman  
  Chief Executive Officer and Chairman of the Board  
  (Principal Executive Officer)  

 

Date: November 14, 2022

 

Reliance Global Group, Inc.  
     
By: /s/ Willian Lebovics  
  William Lebovics  
  Chief Financial Officer  
  (Principal Financial Officer)  

 

Date: November 14, 2022

 

36

 

Reliance Global (NASDAQ:RELI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Reliance Global Charts.
Reliance Global (NASDAQ:RELI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Reliance Global Charts.